GT,Diagnosis 1,ERN Category
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and death in infancy/childhood.

+2. Propionic acidemia: Consistent with metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and death in infancy/childhood.

+3. Vitamin B12 deficiency: Consistent with metabolic acidosis and decreased methylmalonyl-CoA mutase activity, but less likely to cause death in infancy/childhood unless severe.

+4. Inborn errors of metabolism (e.g., isovaleric acidemia, glutaric aciduria type II): Consistent with metabolic acidosis and potential for death in infancy/childhood if left untreated.

+5. Renal failure (severe congenital form): Consistent with metabolic acidosis, but less likely to be associated with decreased methylmalonyl-CoA mutase activity or death in infancy/childhood unless a severe congenital form.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Spinal muscular atrophy (SMA): Motor delay, generalized hypotonia, pneumonia. May not always lead to death in infancy.

+2. Leigh syndrome: Motor delay, generalized hypotonia, death in infancy, elevated urinary carboxylic acid.

+3. Pompe disease: Generalized hypotonia, pneumonia, elevated urinary carboxylic acid, death in infancy.

+4. Congenital muscular dystrophy: Motor delay, generalized hypotonia, pneumonia, death in infancy (in severe cases).

+5. Mitochondrial disorder: Motor delay, generalized hypotonia, death in infancy, elevated urinary carboxylic acid (depending on the specific disorder).",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. May also present with developmental delays or seizures, which were not reported.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential developmental abnormalities or early death. Specific type (e.g., type I, II, III) would need to be determined.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development or birth, and potential neonatal death. Specific syndrome would depend on additional clinical features.

+4. Severe perinatal asphyxia: Consistent with neonatal death and potential developmental abnormalities, but does not explain amino acid abnormalities.

+5. Prematurity complications: Consistent with neonatal death and potential developmental abnormalities, but does not explain amino acid abnormalities.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Congenital muscular dystrophy: Consistent with motor delay, abnormal muscle physiology, and cerebellar involvement. May not fully explain the diaphragmatic hernia or failure to thrive.

+2. Pontocerebellar hypoplasia: Consistent with cerebellar agenesis/atrophy, motor delay, and failure to thrive. May not account for the diaphragmatic hernia.

+3. Walker-Warburg syndrome: Consistent with congenital diaphragmatic hernia, cerebellar abnormalities, motor delay, and failure to thrive. A rare genetic disorder affecting multiple organ systems.

+4. Pena-Shokeir syndrome: Consistent with congenital diaphragmatic hernia, lipodystrophy, and failure to thrive. May not fully explain the neurological symptoms.

+5. Severe congenital diaphragmatic hernia with associated brain malformations: Consistent with the diaphragmatic hernia, cerebellar abnormalities, and failure to thrive. The brain malformations could contribute to the motor delay and other neurological symptoms.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Amino acid metabolism disorder: Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, elevated urinary carboxylic acid, developmental delays, intellectual disability, and potential for early death. Key symptoms not reported: specific metabolic abnormalities or clinical features associated with particular disorders.

+2. Neurodegenerative disorder: Consistent with delayed speech and language development, intellectual disability, motor delay, generalized hypotonia, athetosis, and potential for early death. Key symptoms not reported: specific neurological deficits or progression pattern.

+3. Genetic syndrome or chromosomal abnormality: Consistent with abnormality of prenatal development or birth, delayed speech and language development, intellectual disability, motor delay, generalized hypotonia, kyphoscoliosis, and potential for early death. Key symptoms not reported: specific dysmorphic features or associated anomalies.

+4. Congenital anomaly or birth defect: Consistent with hydronephrosis, abnormality of prenatal development or birth, and potential for early death. Key symptoms not reported: specific structural abnormalities or associated malformations.

+5. Infectious or inflammatory condition: Consistent with fever, opisthotonus (abnormal posturing), and potential for early death. Key symptoms not reported: specific infectious agent or inflammatory process, other associated symptoms (e.g., rash, respiratory symptoms).",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Hypertyrosinemia, hyperphenylalaninemia, skin rash, gastrointestinal inflammation, diarrhea, abnormality of prenatal development or birth. Key symptoms not reported: specific neurological or developmental delays associated with the disorder.

+2. Severe combined immunodeficiency (SCID): Recurrent viral infections, abnormality of prenatal development or birth, death in infancy/childhood. Key symptoms not reported: severe infections from an early age, failure to thrive.

+3. Inflammatory bowel disease (IBD): Gastrointestinal inflammation, diarrhea, skin rash. Key symptoms not reported: abdominal pain, bloody stools, weight loss.

+4. Congenital diaphragmatic hernia: Hernia, abnormality of prenatal development or birth. Key symptoms not reported: respiratory distress, pulmonary hypertension.

+5. Severe dermatological condition: Skin rash (erythematous plaque, macule, papule). Key symptoms not reported: specific skin lesions or distribution patterns associated with the condition.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Mitochondrial disease: Consistent with increased lactate levels, potential for severe complications in infancy. Key symptom not reported: muscle weakness, seizures.

+2. Epidermolysis bullosa: Consistent with skin rash, eczematoid dermatitis, alopecia. Key symptom not reported: blistering of skin and mucous membranes.

+3. Ichthyosis: Consistent with skin rash, eczematoid dermatitis, alopecia. Key symptom not reported: scaling or thickening of skin.

+4. Organic acidemia: Consistent with increased lactate levels, potential for severe complications in infancy. Key symptom not reported: developmental delays, seizures.

+5. Lupus erythematosus: Consistent with skin rash, alopecia. Key symptoms not reported: joint pain, fatigue, photosensitivity.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Lysosomal storage disorder: Consistent with intellectual disability, rod-cone dystrophy, cerebellar atrophy, abnormal facial shape, and lipodystrophy. May not explain acute/chronic hepatitis or thromboembolism.

+2. Mitochondrial disorder: Consistent with rod-cone dystrophy, intellectual disability, cerebellar atrophy, and acute/chronic hepatitis. May not explain abnormal facial shape or lipodystrophy.

+3. Chromosomal abnormality/single-gene disorder: Consistent with intellectual disability, rod-cone dystrophy, cerebellar atrophy, abnormal facial shape, and abnormal calvaria morphology. May not explain hepatitis or thromboembolism.

+4. Congenital infection (e.g., TORCH infections): Consistent with intellectual disability, rod-cone dystrophy, cerebellar atrophy, and abnormal facial shape. May not explain lipodystrophy, hepatitis, or thromboembolism.

+5. Severe perinatal insult (e.g., hypoxic-ischemic encephalopathy): Consistent with intellectual disability, cerebellar atrophy, and death in infancy. May not explain rod-cone dystrophy, abnormal facial shape, lipodystrophy, or hepatitis.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with macrocephaly, lethargy, hypotonia, dystonia, dyskinesia, glutaric aciduria, decreased plasma free carnitine, and potential neonatal death. May not explain cystic hygroma or fever.

+2. Zellweger spectrum disorders (ZSDs): Consistent with macrocephaly, cystic hygroma, lethargy, hypotonia, dystonia, and neonatal death. Do not typically cause glutaric aciduria or decreased carnitine levels.

+3. Congenital infections (e.g., CMV, toxoplasmosis): Consistent with fever, vomiting, diarrhea, dyspnea, drowsiness, and potential neurological symptoms. Do not typically cause macrocephaly, cystic hygroma, or metabolic abnormalities.

+4. Leukodystrophies: Consistent with macrocephaly, neurological symptoms (hypotonia, dystonia, dyskinesia), and potential neonatal death. Do not typically cause cystic hygroma or metabolic abnormalities.

+5. Severe metabolic disorder (unspecified): Consistent with many of the reported symptoms, including macrocephaly, neurological symptoms, metabolic abnormalities, and potential neonatal death. Specific diagnosis uncertain without further testing.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Urea cycle disorder: Consistent with hyperammonemia, lethargy, drowsiness, and potential for neonatal death. Key symptom not reported: vomiting, protein intolerance.

+2. Organic acidemia: Consistent with lethargy, drowsiness, abnormal glycine and carnitine levels, and potential for metabolic crises. Key symptom not reported: vomiting, acidosis.

+3. Fatty acid oxidation disorder: Consistent with lethargy, feeding difficulties, and potential for metabolic decompensation. Key symptom not reported: hypoglycemia, vomiting.

+4. Glycogen storage disease: Consistent with lethargy, feeding difficulties, and potential for failure to thrive. Key symptom not reported: hepatomegaly, hypoglycemia.

+5. Congenital disorder of glycosylation: Consistent with abnormality of prenatal development, lethargy, and potential for multi-system involvement. Key symptom not reported: developmental delay, seizures.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Joubert syndrome: Consistent with microcephaly, intellectual disability, ataxia, hypotonia, nystagmus, cerebellar agenesis/atrophy, and developmental delays. May also involve breathing abnormalities and kidney problems.

+2. Dandy-Walker malformation: Consistent with cerebellar agenesis/atrophy, intellectual disability, motor delays, hypotonia, and ataxia. May also involve hydrocephalus and other brain abnormalities.

+3. Chromosomal abnormality (e.g., trisomy, deletion): Consistent with microcephaly, intellectual disability, growth delay, and developmental delays. Specific chromosomal abnormalities may have additional associated features.

+4. Inborn error of metabolism: Consistent with microcephaly, intellectual disability, encephalopathy, and developmental delays. May also involve seizures, metabolic abnormalities, and organ dysfunction.

+5. Neurodegenerative disorder (e.g., ataxia-telangiectasia): Consistent with cerebellar atrophy, ataxia, and hyporeflexia. Typically progressive, but some forms may present at birth or early childhood.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Organic acidemia: Consistent with methylmalonic aciduria, hyperammonemia, developmental delays, and potential for early death. Key symptoms not reported: vomiting, lethargy, and metabolic acidosis.

+2. Mitochondrial disorder: Consistent with optic atrophy, nystagmus, developmental delays, hypotonia, and potential for early death. Key symptoms not reported: seizures, lactic acidosis, and muscle weakness.

+3. Congenital disorder of glycosylation (CDG): Consistent with developmental delays, hypotonia, and abnormal metabolic markers. Key symptoms not reported: failure to thrive, coagulopathy, and liver dysfunction.

+4. Peroxisomal disorder (e.g., Zellweger syndrome): Consistent with developmental delays, hypotonia, optic atrophy, and metabolic abnormalities. Key symptoms not reported: craniofacial dysmorphism, liver dysfunction, and hearing loss.

+5. Amino acid metabolism disorder (e.g., maple syrup urine disease, homocystinuria): Consistent with hyperhomocystinemia, hyperalaninemia, developmental delays, and potential for early death. Key symptoms not reported: maple syrup odor (in maple syrup urine disease), thrombosis (in homocystinuria).",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Consistent with hypoglycemia, vomiting, diarrhea, and abnormal carnitine levels. May not explain elevated transaminases.

+2. Organic acidemia: Consistent with hypoglycemia, vomiting, diarrhea, and abnormal carnitine levels. May not explain elevated transaminases.

+3. Biliary atresia: Consistent with elevated transaminases, vomiting, and diarrhea. May not explain hypoglycemia or abnormal carnitine levels.

+4. Neonatal hepatitis: Consistent with elevated transaminases, vomiting, and diarrhea. May not explain hypoglycemia or abnormal carnitine levels.

+5. Congenital disorder of glycosylation: Consistent with hypoglycemia, vomiting, diarrhea, and elevated transaminases. May not explain abnormal carnitine levels.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid, hyperkalemia, hyponatremia, and potentially severe symptoms like coma and early death. Key symptoms not reported: specific metabolic abnormalities or organ involvement depending on the type of organic acidemia.

+2. Fatty acid oxidation disorder: Consistent with hyperkalemia, hyponatremia, and potentially severe symptoms like coma and early death. Key symptoms not reported: hypoglycemia, liver dysfunction, cardiomyopathy.

+3. Severe respiratory disorder: Consistent with respiratory acidosis and potentially coma in severe cases. Key symptoms not reported: specific respiratory symptoms like dyspnea, cyanosis, or abnormal breath sounds.

+4. Severe neurological condition: Consistent with coma and potentially early death. Key symptoms not reported: specific neurological deficits, seizures, or developmental delays.

+5. Renal failure: Consistent with hyperkalemia, hyponatremia, and potentially severe symptoms like coma and early death. Key symptoms not reported: oliguria, edema, or other signs of kidney dysfunction.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria: Consistent with hyperhomocystinemia, hypermethioninemia, ectopia lentis, intellectual disability. May not involve large hands or long foot.

+2. Marfan syndrome: Consistent with ptosis, ectopia lentis, long limbs. Does not explain metabolic abnormalities or intellectual disability.

+3. Sotos syndrome: Consistent with intellectual disability, motor delay, large hands and feet. Does not explain metabolic or ocular symptoms.

+4. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): Consistent with intellectual disability, skeletal abnormalities. Does not typically involve the reported metabolic or ocular symptoms.

+5. Congenital disorder of glycosylation: A group of metabolic disorders that can cause intellectual disability, developmental delays, and various other symptoms. May potentially explain some of the reported symptoms, but more information is needed.",Hereditary metabolic disorders
[],"+1. Congenital disorders of glycosylation (CDG): Consistent with seizures, hypoglycemia, feeding difficulties, and potential developmental delays. May not explain abnormal hemoglobin or early death.

+2. Zellweger syndrome: Consistent with seizures, hypoglycemia, facial dysmorphism (wide mouth, epicanthus), and developmental delays. May not explain abnormal hemoglobin or early death.

+3. Maple syrup urine disease (MSUD): Consistent with seizures, hypoglycemia, and feeding difficulties. Does not explain facial features, abnormal hemoglobin, or early death.

+4. Trisomy 21 (Down syndrome): Consistent with wide mouth, epicanthus, and sparse hair. Does not explain seizures, hypoglycemia, abnormal hemoglobin, or early death.

+5. Sickle cell disease: Consistent with abnormal hemoglobin. Does not explain other symptoms such as seizures, hypoglycemia, facial features, or early death.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Inborn error of metabolism: Consistent with hyperammonemia, hyperglycinemia, hypoglycinemia, abnormal circulating carnitine concentration, hepatomegaly, and neurological symptoms. Key symptoms not reported: specific metabolic abnormalities depending on the disorder.

+2. Mitochondrial disorder: Consistent with intellectual disability, seizures, motor delay, and metabolic abnormalities. Key symptoms not reported: muscle weakness, vision or hearing problems, lactic acidosis.

+3. Urea cycle disorder: Consistent with hyperammonemia, intellectual disability, seizures, and neonatal/early-onset presentation. Key symptoms not reported: vomiting, lethargy, respiratory distress.

+4. Organic acidemia: Consistent with intellectual disability, seizures, metabolic abnormalities, and potential neonatal/early-onset presentation. Key symptoms not reported: specific metabolic abnormalities depending on the disorder.

+5. Chromosomal abnormality or genetic syndrome: Consistent with abnormality of prenatal development or birth, intellectual disability, seizures, motor delay, and potential congenital anomalies. Key symptoms not reported: specific dysmorphic features or malformations depending on the syndrome.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with methylmalonic aciduria, decreased methylmalonyl-CoA mutase activity, metabolic acidosis, hypotonia, feeding difficulties, and neonatal death. Key symptoms not reported: developmental delay, seizures, and kidney disease.

+2. Leukodystrophy: Consistent with abnormal nervous system physiology and hypotonia. Key symptoms not reported: progressive neurological deterioration, vision and hearing problems, and specific white matter changes on brain imaging.

+3. Mitochondrial disorder: Consistent with hypotonia, metabolic acidosis, and feeding difficulties. Key symptoms not reported: specific organ involvement (e.g., cardiomyopathy, myopathy, or neurological manifestations), and elevated lactate levels.

+4. Congenital disorder of glycosylation: Consistent with hypotonia, feeding difficulties, and abnormal nervous system physiology. Key symptoms not reported: developmental delay, seizures, and specific organ involvement (e.g., liver, kidney, or heart).

+5. Severe combined immunodeficiency (SCID): Consistent with leukopenia and thrombocytopenia. Key symptoms not reported: recurrent infections, failure to thrive, and specific immunological abnormalities.",Hereditary metabolic disorders
['Systemic primary carnitine deficiency'],"+1. Organic acidemia: Consistent with hypoglycemia, vomiting, abnormal amino acid levels, and metabolic derangements. May not fully explain coma, sudden death, or elevated alkaline phosphatase.

+2. Fatty acid oxidation disorder: Consistent with hypoglycemia, vomiting, decreased carnitine levels, and metabolic abnormalities. Does not typically cause elevated alkaline phosphatase.

+3. Mitochondrial disorder: Consistent with metabolic crises, lactic acidosis, and multi-organ involvement. Amino acid abnormalities and elevated alkaline phosphatase are not characteristic.

+4. Urea cycle disorder: Consistent with metabolic decompensation, coma, and sudden death. Specific amino acid abnormalities are not typical.

+5. Liver disease: Consistent with elevated alkaline phosphatase and metabolic derangements. Does not fully explain the amino acid abnormalities or sudden death.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Inborn error of metabolism: Lethargy, drowsiness, feeding difficulties, decreased plasma free carnitine. Key missing symptom: specific metabolic abnormalities on screening tests.

+2. Leukodystrophy or neuronal ceroid lipofuscinosis: Clumsiness, poor coordination, sleep abnormality, death in childhood. Key missing symptom: specific neuroimaging findings.

+3. Congenital muscular dystrophy: Poor coordination, feeding difficulties, death in infancy/childhood. Key missing symptom: muscle weakness or specific muscle biopsy findings.

+4. Zellweger spectrum disorder: Lethargy, poor coordination, death in infancy/childhood. Key missing symptom: specific dysmorphic features or neuroimaging findings.

+5. Leigh syndrome: Lethargy, poor coordination, death in infancy/childhood. Key missing symptom: specific neuroimaging findings (e.g., bilateral symmetric lesions in the basal ganglia or brainstem).",Hereditary metabolic disorders
[],"+1. Leukodystrophy: Consistent with delayed speech/language development, encephalopathy, spastic diplegia/tetraplegia, and progressive course. May not fully explain hypothyroidism or recurrent infections.

+2. Mitochondrial disorder: Consistent with encephalopathy, spastic diplegia/tetraplegia, cytochrome c oxidase-negative muscle fibers, and progressive course. May not explain hypothyroidism or recurrent infections.

+3. Cerebral palsy: Consistent with delayed speech/language development, dysarthria, spastic diplegia/tetraplegia. May not explain encephalopathy, hypothyroidism, recurrent infections, or progressive course.

+4. Inborn error of metabolism (e.g., glycine encephalopathy): Consistent with encephalopathy, abnormal glycine concentration, and progressive course. May not fully explain motor symptoms or recurrent infections.

+5. Combined immunodeficiency disorder: Consistent with recurrent viral infections. May not explain neurological, motor, or metabolic symptoms.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Abnormal circulating carnitine concentration, potentially leading to developmental abnormalities and early death.

+2. Congenital malformation: Abnormality of prenatal development or birth, which could be due to structural defects present at birth.

+3. Chromosomal abnormality: Abnormality of prenatal development or birth, potentially caused by chromosomal disorders like trisomies or deletions.

+4. Intrauterine infection: Abnormality of prenatal development or birth, which could be a consequence of infections during pregnancy (e.g., cytomegalovirus, rubella, Zika virus).

+5. Placental insufficiency: Abnormality of prenatal development or birth, potentially due to inadequate placental function leading to intrauterine growth restriction and developmental abnormalities.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with glutaric aciduria, macrocephaly, hypotonia, dystonia, and metabolic acidosis. Key symptom not reported: acute encephalopathic crisis.

+2. Organic acidemia: Consistent with metabolic acidosis, lethargy, vomiting, and other systemic symptoms. Specific type not specified based on given information.

+3. Fatty acid oxidation disorder: Consistent with metabolic acidosis, lethargy, hypotonia, and decreased plasma free carnitine. Specific disorder not specified.

+4. Zellweger spectrum disorder: Consistent with macrocephaly, cystic hygroma, hypotonia, and other congenital anomalies. Key symptom not reported: characteristic facial features.

+5. Severe infection (e.g., meningitis, encephalitis): Consistent with fever, vomiting, lethargy, and neurological symptoms like dystonia and dyskinesia. Specific type not specified.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and developmental abnormalities. Key symptom not reported: musty odor in urine, skin, and sweat.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential liver and kidney problems. Key symptoms not reported: eye and skin abnormalities, liver disease.

+3. Maple syrup urine disease (MSUD): Consistent with developmental delays and potential amino acid imbalances. Key symptom not reported: maple syrup odor in urine and sweat.

+4. Homocystinuria: Consistent with developmental delays and potential vision problems. Key symptoms not reported: blood clots, skeletal abnormalities.

+5. Urea cycle disorders: Consistent with potential brain damage and developmental delays. Key symptoms not reported: vomiting, lethargy, and respiratory distress.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. Leukodystrophy: Delayed speech and language development, intellectual disability, hyperreflexia, difficulty walking, abnormal cerebral white matter morphology, difficulty climbing stairs, difficulty running. Key symptom not reported: Vision problems.

+2. Neurodegenerative disorder: Delayed speech and language development, intellectual disability, hyperreflexia, difficulty walking, abnormal cerebral white matter morphology, difficulty climbing stairs, difficulty running, death in infancy, death in childhood. Key symptom not reported: Seizures.

+3. Cerebral palsy: Delayed speech and language development, intellectual disability, difficulty walking, abnormal cerebral white matter morphology, difficulty climbing stairs, difficulty running. Key symptoms not reported: Muscle stiffness, abnormal muscle tone.

+4. Chromosomal abnormality: Delayed speech and language development, intellectual disability, difficulty walking, difficulty climbing stairs, difficulty running. Key symptoms not reported: Distinctive physical features, congenital malformations.

+5. Metabolic disorder: Delayed speech and language development, intellectual disability, hyperreflexia, difficulty walking, abnormal cerebral white matter morphology, difficulty climbing stairs, difficulty running, death in infancy, death in childhood. Key symptom not reported: Organomegaly (enlarged organs).",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, hypoglycemia, and early mortality. Key symptoms not reported: maple syrup odor in urine and cerumen (earwax).

+2. Leigh syndrome: Consistent with apathy, spasticity, generalized hypotonia, and early mortality. Key symptoms not reported: respiratory abnormalities, seizures, and developmental delays.

+3. Prader-Willi syndrome: Consistent with obesity, hypotonia, and developmental delays (implied by apathy). Key symptoms not reported: short stature, hypogonadism, and characteristic facial features.

+4. Mitochondrial encephalomyopathy: Consistent with apathy, spasticity, generalized hypotonia, and early mortality. Key symptoms not reported: seizures, vision and hearing problems, and developmental delays.

+5. Leukodystrophy: Consistent with spasticity, hypotonia, and early mortality. Key symptoms not reported: progressive cognitive and motor decline, seizures, and vision problems.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Galactosemia: Consistent with hypergalactosemia, abnormality of galactoside metabolism, increased bilirubin, and potential for severe complications. Key symptom not reported: jaundice, vomiting, failure to thrive.

+2. Phenylketonuria (PKU): Consistent with delayed speech and language development, hyperalaninemia, and abnormal amino acid concentrations. Key symptom not reported: musty odor, fair skin and hair, seizures.

+3. Maple syrup urine disease (MSUD): Consistent with delayed speech and language development, aminoaciduria, and abnormal amino acid concentrations. Key symptom not reported: maple syrup odor, lethargy, seizures.

+4. Urea cycle disorders: Consistent with hyperalaninemia, aminoaciduria, and potential for severe complications. Key symptoms not reported: lethargy, vomiting, respiratory distress, seizures.

+5. Lesch-Nyhan syndrome: Consistent with delayed speech and language development. Key symptoms not reported: self-mutilating behavior, gout, neurological abnormalities.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Organic acidemia: Consistent with metabolic acidosis, dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid. May not explain hyperammonemia or abnormal glycine levels.

+2. Urea cycle disorder: Consistent with hyperammonemia and metabolic acidosis. May not explain organic acidurias or abnormal glycine levels.

+3. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration. May not explain organic acidurias or hyperammonemia.

+4. Mitochondrial disorder: Consistent with metabolic acidosis and potentially elevated organic acids. May not explain hyperammonemia or abnormal glycine levels.

+5. Severe liver disease: Consistent with hyperammonemia and metabolic acidosis. May not explain organic acidurias or abnormal glycine levels.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Methylmalonic acidemia: Consistent with hyperhomocystinemia, hypomethioninemia, abnormality of folate metabolism, and progressive neurologic deterioration. May also cause anemia and recurrent infections.

+2. Leukodystrophy (e.g., Krabbe disease, Metachromatic leukodystrophy): Matches generalized hypotonia, progressive neurologic deterioration, and death in childhood. However, the patient did not report specific neurological symptoms like seizures or vision loss.

+3. Niemann-Pick disease type C: Aligns with jaundice, hypotonia, neurologic deterioration, and death in childhood. However, the patient did not report hepatosplenomegaly or vertical supranuclear gaze palsy.

+4. Acute intermittent porphyria: Consistent with jaundice and abnormal circulating porphyrin concentration. However, the patient did not report abdominal pain, neuropsychiatric symptoms, or photosensitivity.

+5. Hereditary folate malabsorption: Matches anemia, hyperhomocystinemia, and abnormality of folate metabolism. However, the patient did not report diarrhea or failure to thrive.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Hypertyrosinemia, hyperphenylalaninemia, abnormality of prenatal development, and early death are consistent with this diagnosis. Key symptoms not reported: specific metabolic abnormalities or clinical manifestations depending on the disorder.

+2. Congenital airway anomaly: Upper airway obstruction, abnormality of prenatal development, and early death are consistent with this diagnosis. Key symptoms not reported: specific anatomical defects or associated complications.

+3. Chronic lung disease: Chronic pulmonary obstruction and early death are consistent with this diagnosis. Key symptoms not reported: specific respiratory symptoms or complications.

+4. Chromosomal abnormality: Abnormality of prenatal development and early death are consistent with this diagnosis. Key symptoms not reported: specific dysmorphic features or associated anomalies.

+5. Congenital heart defect: Abnormality of prenatal development and early death are consistent with this diagnosis. Key symptoms not reported: specific cardiac symptoms or complications.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Organic acidemia: Consistent with seizures, spasticity, fatigue, and elevated urinary carboxylic acid. May not explain alopecia or dyspnea.

+2. Leukodystrophy: Consistent with seizures, spasticity, and death in infancy. May not explain alopecia, dyspnea, or elevated carboxylic acid.

+3. Mitochondrial disorder: Consistent with seizures, spasticity, fatigue, dyspnea, and multi-system involvement. May not explain alopecia or elevated carboxylic acid.

+4. Peroxisomal disorder: Consistent with seizures, spasticity, fatigue, and elevated carboxylic acid. May not explain alopecia, dyspnea, or death in infancy.

+5. Chromosomal abnormality or genetic syndrome: Consistent with the combination of neurological, metabolic, and multi-system symptoms. Specific features may vary depending on the underlying condition.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism (e.g., phenylketonuria, tyrosinemia): Consistent with hypertyrosinemia, hyperphenylalaninemia, and potentially other symptoms if left untreated.

+2. Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis): Consistent with gastrointestinal inflammation, fever, and vomiting.

+3. Mitochondrial disorder or lysosomal storage disorder: Consistent with multi-organ involvement, including metabolic abnormalities, inflammation, and early mortality.

+4. Congenital infection (e.g., cytomegalovirus, rubella): Consistent with fever, vomiting, and early mortality, but may not fully explain metabolic abnormalities.

+5. Cancer (e.g., leukemia, lymphoma): Consistent with fever, vomiting, and early mortality, but less likely to explain metabolic abnormalities and obesity.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Glycine encephalopathy: Consistent with metabolic acidosis, increased CSF lactate, aminoaciduria, abnormal circulating glycine concentration. Does not typically cause skin rash or alopecia.

+2. Organic acidemia: Consistent with metabolic acidosis, aminoaciduria, elevated urinary carboxylic acid. Skin rash and alopecia are not common features.

+3. Erythroderma: Consistent with skin rash (erythematous plaque, macule, papule). Does not explain metabolic abnormalities or aminoaciduria.

+4. Leukocyte adhesion deficiency: Consistent with skin rash. Does not explain metabolic abnormalities or aminoaciduria.

+5. Metabolic syndrome: Skin rash can sometimes occur, but does not explain the severe metabolic and neurological symptoms.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with decreased methylmalonyl-CoA mutase activity, feeding difficulties, dehydration, and potential for neonatal/infant death. Key symptom not reported: metabolic acidosis.

+2. Organic acidemia: Consistent with feeding difficulties, dehydration, and potential for neonatal/infant death. Common symptoms not reported: vomiting, lethargy, seizures.

+3. Urea cycle disorder: Consistent with feeding difficulties, dehydration, and potential for neonatal/infant death. Common symptoms not reported: hyperammonemia, neurological symptoms.

+4. Congenital heart defect: Consistent with potential for neonatal/infant death. Common symptoms not reported: cyanosis, respiratory distress, poor feeding.

+5. Chromosomal abnormality: Consistent with potential for neonatal/infant death and feeding difficulties. Common symptoms not reported: dysmorphic features, developmental delays.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Propionic acidemia: Consistent with metabolic acidosis, increased lactate, propionyl-CoA carboxylase deficiency, aminoaciduria, and elevated urinary carboxylic acid. Key symptoms not reported: vomiting, protein intolerance, and developmental delay.

+2. Methylmalonic acidemia: Consistent with metabolic acidosis, increased lactate, aminoaciduria, and elevated urinary carboxylic acid. Key symptoms not reported: vomiting, protein intolerance, and developmental delay.

+3. Mitochondrial disorder: Consistent with lethargy, hypotonia, metabolic acidosis, increased lactate, and fatigue. Key symptoms not reported: seizures, muscle weakness, and developmental delay.

+4. Glycine encephalopathy: Consistent with lethargy, hypotonia, abnormal glycine concentration, and aminoaciduria. Key symptoms not reported: seizures, developmental delay, and intellectual disability.

+5. Urea cycle disorder: Consistent with lethargy, hypotonia, aminoaciduria, and metabolic acidosis. Key symptoms not reported: vomiting, protein intolerance, and developmental delay.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential developmental abnormalities/early death if untreated. Key symptom not reported: intellectual disability.

+2. Tyrosinemia type I: Consistent with hypertyrosinemia, developmental abnormalities, and potential early death if untreated. Key symptoms not reported: liver disease, kidney disease, neurological symptoms.

+3. Congenital malformations/genetic disorders: Consistent with abnormalities of prenatal development and potential early death. Additional information on specific malformations or genetic testing results would be helpful.

+4. Perinatal asphyxia/complications: Consistent with neonatal death and potential developmental abnormalities. Additional details on the pregnancy, delivery, and neonatal course would be useful.

+5. Severe prematurity: Consistent with neonatal death and potential developmental abnormalities. Gestational age and birth weight information would help assess the likelihood of this diagnosis.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. 3-Methylglutaconic aciduria (3-MGA): Consistent with dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid. May not explain death in infancy in all cases.

+2. Glutaric aciduria type I (GA-I): Consistent with 3-methylglutaric aciduria, dicarboxylic aciduria, and elevated urinary carboxylic acid. Can lead to severe complications and potentially death in infancy.

+3. Methylmalonic acidemia (MMA): Consistent with dicarboxylic aciduria and elevated urinary carboxylic acid. May not fully explain 3-methylglutaric aciduria.

+4. Propionic acidemia (PA): Consistent with dicarboxylic aciduria and elevated urinary carboxylic acid. May not fully explain 3-methylglutaric aciduria.

+5. Isovaleric acidemia (IVA): Consistent with dicarboxylic aciduria and elevated urinary carboxylic acid. May not fully explain 3-methylglutaric aciduria or death in infancy.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Consistent with carious teeth, elevated transaminases, abnormal copper metabolism (decreased circulating copper, increased urinary copper, decreased ceruloplasmin), and potential for severe complications leading to death in childhood. Key symptom not reported: neurological or psychiatric manifestations.

+2. Porphyria: Consistent with abnormal circulating porphyrin and amino acid concentrations. Key symptoms not reported: abdominal pain, neurological symptoms, photosensitivity.

+3. Hemochromatosis: Consistent with decreased circulating iron concentration. Key symptoms not reported: fatigue, joint pain, skin discoloration.

+4. Nutritional deficiency: Consistent with carious teeth and obesity, which may contribute to metabolic abnormalities. Additional information on diet and nutritional status is needed.

+5. Inborn error of metabolism: The combination of symptoms suggests a potential metabolic disorder affecting various pathways. Specific diagnosis would require further testing and evaluation.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Abnormal circulating carnitine concentration, potential developmental abnormalities and early mortality. Key symptoms not reported: specific metabolic derangements, organ involvement.

+2. Congenital malformation: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific details about the malformations.

+3. Chromosomal abnormality: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific chromosomal abnormality, associated dysmorphic features.

+4. Perinatal complications: Abnormality of prenatal development or birth, potential for neonatal death. Key symptoms not reported: specific details about the complications during pregnancy, labor, or delivery.

+5. Congenital infection: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific infectious agent, characteristic clinical findings.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia and death in infancy/childhood. Key symptom not reported: liver disease.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Key symptoms not reported: intellectual disability, seizures.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections. Key symptom not reported: failure to thrive.

+4. Leukocyte adhesion deficiency (LAD): Consistent with recurrent viral infections. Key symptoms not reported: delayed separation of the umbilical cord, recurrent bacterial/fungal infections.

+5. Organic acidemia: Consistent with death in infancy/childhood and hypertyrosinemia (in some cases). Key symptoms not reported: metabolic acidosis, developmental delay.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration, aminoaciduria, and elevated urinary carboxylic acid.

+2. Organic acidemia: Consistent with aminoaciduria and elevated urinary carboxylic acid. Specific organic acid levels would help narrow down the diagnosis.

+3. Carnitine deficiency: Consistent with abnormal circulating carnitine concentration. Primary or secondary deficiency would need to be determined.

+4. Renal tubular disorder: Consistent with aminoaciduria, but other reported symptoms are not typical.

+5. Liver disease: Aminoaciduria and abnormal amino acid levels can occur, but additional liver function tests would be needed for confirmation.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Mitochondrial disorder: Consistent with generalized hypotonia, death in infancy, hepatomegaly, tachypnea, 3-methylglutaconic aciduria, and feeding difficulties.

+2. Organic acidemia: Consistent with 3-methylglutaconic aciduria, but may not fully explain all symptoms.

+3. Congenital muscular dystrophy: Consistent with generalized hypotonia and feeding difficulties, but does not typically present with other reported symptoms.

+4. Lysosomal storage disorder: Consistent with hepatomegaly and feeding difficulties, but does not typically present with other reported symptoms.

+5. Congenital disorder of glycosylation: Consistent with hypotonia, hepatomegaly, and feeding difficulties, but does not typically present with other reported symptoms.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Urea cycle disorder: Consistent with hyperammonemia, respiratory alkalosis, lethargy, developmental delays, and potential neonatal/childhood death. May also explain elevated plasma citrulline and liver dysfunction.

+2. Organic acidemia: Consistent with hypoglycemia, lethargy, developmental delays, and potential neonatal/childhood death. May also contribute to metabolic abnormalities and liver dysfunction.

+3. Mitochondrial disorder: Consistent with developmental delays, hypoglycemia, hypothermia, lethargy, and potential multi-system involvement. May also explain liver dysfunction and obesity.

+4. Congenital infection (e.g., cytomegalovirus, toxoplasmosis): Consistent with developmental delays, abnormality of prenatal development or birth, and potential neurological symptoms. May also contribute to liver dysfunction and other systemic manifestations.

+5. Genetic syndrome (e.g., peroxisomal disorders, lysosomal storage disorders): Consistent with developmental delays, hypoglycemia, hyperhidrosis, obesity, and potential multi-system involvement. May also explain liver dysfunction and other metabolic abnormalities.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric aciduria type 1 (GA1): Consistent with macrocephaly, seizures, hypotonia, and glutaric aciduria. May not explain visual evoked potential abnormalities or athetosis.

+2. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with macrocephaly, seizures, hypotonia, and visual evoked potential abnormalities. May not explain glutaric aciduria.

+3. Canavan disease: Consistent with macrocephaly, seizures, hypotonia, and neonatal death. May not explain visual evoked potential abnormalities or glutaric aciduria.

+4. Alexander disease: Consistent with macrocephaly, seizures, and athetosis. May not explain visual evoked potential abnormalities, glutaric aciduria, or neonatal death.

+5. Severe brain malformation or injury: Consistent with macrocephaly, seizures, hypotonia, and visual evoked potential abnormalities. May not explain glutaric aciduria or specific symptoms like athetosis.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1. Tyrosinemia type I: Delayed speech and language development, hypertyrosinemia, elevated urinary delta-aminolevulinic acid. Does not typically cause 4-hydroxyphenylpyruvic aciduria.

+2. Succinic semialdehyde dehydrogenase deficiency: Delayed speech and language development, elevated urinary delta-aminolevulinic acid, death in childhood. Does not typically cause 4-hydroxyphenylpyruvic aciduria or hypertyrosinemia.

+3. Phenylketonuria (PKU): Delayed speech and language development, abnormal circulating phenylalanine concentration. Does not typically cause 4-hydroxyphenylpyruvic aciduria, elevated delta-aminolevulinic acid, or hypertyrosinemia.

+4. Hawkinsinuria: 4-Hydroxyphenylpyruvic aciduria. Does not typically cause delayed speech/language development, elevated delta-aminolevulinic acid, hypertyrosinemia, or death in childhood.

+5. Combined metabolic disorder: A combination of multiple metabolic disorders may explain the diverse range of symptoms, including delayed development, 4-hydroxyphenylpyruvic aciduria, elevated delta-aminolevulinic acid, hypertyrosinemia, and potential early death.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, abnormal prenatal development, and potential death in infancy/childhood if untreated. Key symptom not reported: intellectual disability.

+2. Tyrosinemia: Consistent with hypertyrosinemia, abnormal prenatal development, and potential death in infancy/childhood if untreated. Key symptoms not reported: liver disease, kidney disease, neurological issues.

+3. Congenital malformation syndrome: Consistent with abnormal prenatal development and potential death in infancy/childhood. Additional symptoms depend on the specific syndrome.

+4. Chromosomal abnormality: Consistent with abnormal prenatal development and potential death in infancy/childhood. Additional symptoms depend on the specific chromosomal disorder.

+5. Obesity syndrome: Consistent with obesity in infancy/childhood. Additional symptoms depend on the specific syndrome or underlying cause.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with intellectual disability, seizures, hyperphenylalaninemia, and early death. Key symptom not reported: fair skin and hair.

+2. Tyrosinemia: Consistent with intellectual disability, seizures, hypertyrosinemia, elevated urinary carboxylic acid, and early death. Key symptom not reported: liver dysfunction.

+3. Lesch-Nyhan syndrome: Consistent with hyperactivity, intellectual disability, seizures, and self-mutilating behavior (not reported).

+4. Down syndrome: Consistent with intellectual disability, short stature, and developmental delays. Key symptoms not reported: characteristic facial features, congenital heart defects.

+5. Mitochondrial disorder: Consistent with intellectual disability, seizures, short stature, and multi-system involvement. Key symptoms not reported: muscle weakness, vision or hearing problems.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with methylmalonic acidemia, methylmalonic aciduria, metabolic acidosis, hyperammonemia, vomiting, and potentially the neurological symptoms (seizures, hypotonia, neonatal death).

+2. Organic acidemia: Consistent with metabolic acidosis, hyperammonemia, vomiting, and potentially the neurological symptoms. May not fully explain the specific finding of methylmalonic acidemia/aciduria.

+3. Urea cycle disorder: Consistent with hyperammonemia, metabolic acidosis, vomiting, and potentially the neurological symptoms. May not fully explain the specific finding of methylmalonic acidemia/aciduria.

+4. Mitochondrial disorder: Consistent with metabolic acidosis, seizures, hypotonia, and potentially other neurological symptoms. May not fully explain the hematological abnormalities (thrombocytopenia, leukopenia) or the specific finding of methylmalonic acidemia/aciduria.

+5. Congenital lactic acidosis: Consistent with metabolic acidosis and potentially the neurological symptoms. May not fully explain the hematological abnormalities, hyperammonemia, or the specific finding of methylmalonic acidemia/aciduria.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Abnormal circulating carnitine concentration, potential developmental abnormalities and early mortality. Key symptoms not reported: specific metabolic derangements, organ involvement.

+2. Congenital malformation: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific details about the malformations.

+3. Chromosomal abnormality: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific chromosomal abnormality, associated dysmorphic features.

+4. Perinatal complications: Abnormality of prenatal development or birth, potential for neonatal death. Key symptoms not reported: specific details about the complications.

+5. Genetic syndrome: Abnormality of prenatal development or birth, potential for early mortality. Key symptoms not reported: specific syndrome features (e.g., dysmorphic features, organ involvement).",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with methylmalonic aciduria, metabolic acidosis, hyperammonemia, and vomiting. Key symptom not reported: developmental delays or neurological symptoms.

+2. Propionic acidemia: Consistent with metabolic acidosis, hyperammonemia, and vomiting. Key symptom not reported: developmental delays or neurological symptoms.

+3. Urea cycle disorders: Consistent with hyperammonemia, metabolic acidosis, and vomiting. Key symptoms not reported: neurological symptoms, respiratory distress.

+4. Liver disease (e.g., neonatal hepatitis, biliary atresia): Consistent with metabolic acidosis, hyperammonemia, and vomiting. Key symptom not reported: jaundice or other signs of liver dysfunction.

+5. Sepsis: Consistent with metabolic acidosis and vomiting. Key symptoms not reported: fever, elevated inflammatory markers, positive blood cultures.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, seizures, cerebral edema, oroticaciduria, and neonatal death. Key symptoms not reported may include vomiting, lethargy, and respiratory distress.

+2. Ornithine transcarbamylase deficiency (OTC): A specific urea cycle disorder consistent with all reported symptoms. May also present with protein avoidance and developmental delays.

+3. Carbamoyl phosphate synthetase I deficiency (CPS1): Another urea cycle disorder that fits the symptom profile. May also cause lethargy, poor feeding, and respiratory alkalosis.

+4. Citrullinemia: A urea cycle disorder characterized by hyperammonemia, seizures, and cerebral edema. Oroticaciduria and neonatal death can occur in severe cases.

+5. Argininosuccinic aciduria: A urea cycle disorder that can present with hyperammonemia, seizures, cerebral edema, and oroticaciduria. May also cause vomiting, lethargy, and tachypnea.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Leigh syndrome: Consistent with seizures, generalized hypotonia, growth delay, death in infancy, and elevated urinary carboxylic acid. Alopecia and fasciculations are not typical symptoms.

+2. Mitochondrial disorders: Consistent with seizures, generalized hypotonia, growth delay, death in infancy, and elevated urinary carboxylic acid. Alopecia and fasciculations are less common symptoms.

+3. Organic acidemias: Consistent with seizures, generalized hypotonia, growth delay, death in infancy, and elevated urinary carboxylic acid. Alopecia and fasciculations are not typical symptoms.

+4. Leukodystrophies: Consistent with seizures, generalized hypotonia, growth delay, and death in infancy. Elevated urinary carboxylic acid, alopecia, and fasciculations are less common symptoms.

+5. Spinal muscular atrophy (SMA): Consistent with generalized hypotonia and fasciculations. However, seizures, growth delay, death in infancy, alopecia, and elevated urinary carboxylic acid are not typical of SMA.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Familial hypercholesterolemia: Consistent with obesity and hypercholesterolemia, but does not explain hypertyrosinemia and hyperphenylalaninemia.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, but does not explain obesity, hypercholesterolemia, or hypertyrosinemia.

+3. Tyrosinemia: Consistent with hypertyrosinemia, but does not fully explain the other symptoms.

+4. Lysosomal storage disorder: Consistent with obesity and hypercholesterolemia, but typically does not involve high tyrosine or phenylalanine levels.

+5. Multiple enzyme deficiencies: Potentially consistent with all reported symptoms, suggesting a complex metabolic disorder involving deficiencies in multiple enzymes.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Hypertyrosinemia, hyperphenylalaninemia, severe short stature, neonatal death. Key symptoms not reported: specific metabolic abnormalities, developmental delays, or organ dysfunction.

+2. Chromosomal abnormality: Severe short stature, hypospadias, neonatal death. Key symptoms not reported: specific dysmorphic features, intellectual disability, or other congenital anomalies.

+3. Congenital adrenal hyperplasia (CAH): Hypospadias, severe short stature. Key symptoms not reported: virilization, electrolyte imbalances, or adrenal insufficiency.

+4. Prematurity complications: Premature birth, hernia, neonatal death. Key symptoms not reported: respiratory distress, feeding difficulties, or other complications of prematurity.

+5. Congenital malformation syndrome: Hypospadias, severe short stature, neonatal death. Key symptoms not reported: specific pattern of congenital anomalies or dysmorphic features.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with microcephaly, low-set ears, wide nasal bridge, strabismus, syndactyly, developmental delays, intellectual disability, motor delays, short stature, and elevated 7/8-dehydrocholesterol levels. May not exhibit all reported symptoms.

+2. Down syndrome: Consistent with intellectual disability, motor delays, short stature, and some physical features like low-set ears and wide nasal bridge. Does not typically involve cholesterol abnormalities or severe growth retardation.

+3. Cornelia de Lange syndrome: Consistent with intellectual disability, motor delays, short stature, and some physical features like synophrys (fused eyebrows) and limb abnormalities. Does not typically involve cholesterol abnormalities or severe growth retardation.

+4. Seckel syndrome: Consistent with severe short stature, intellectual disability, and some physical features like microcephaly. Does not typically involve cholesterol abnormalities or syndactyly.

+5. Desmosterolosis: Consistent with elevated cholesterol precursors (desmosterol) and some physical features like syndactyly. May not fully explain the extent of developmental delays and other physical features reported.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with glutaric aciduria, elevated circulating glutaric acid concentration, neurological symptoms (ataxia, opisthotonus, athetosis, progressive neurologic deterioration), and metabolic abnormalities (decreased plasma free carnitine, abnormal circulating acylcarnitine concentration). Key symptoms not reported: macrocephaly, hypotonia, seizures.

+2. Methylmalonic acidemia: Consistent with neurological symptoms, metabolic abnormalities (decreased plasma free carnitine, abnormal circulating acylcarnitine concentration), and potential for early death. Key symptoms not reported: lethargy, vomiting, failure to thrive.

+3. Propionic acidemia: Consistent with neurological symptoms, metabolic abnormalities (decreased plasma free carnitine, abnormal circulating acylcarnitine concentration), and potential for early death. Key symptoms not reported: lethargy, vomiting, protein intolerance.

+4. Mitochondrial disorder: Consistent with neurological symptoms, progressive deterioration, and potential metabolic abnormalities. Key symptoms not reported: muscle weakness, exercise intolerance, vision/hearing problems.

+5. Leigh syndrome: Consistent with progressive neurological deterioration, ataxia, and potential metabolic abnormalities. Key symptoms not reported: hypotonia, respiratory difficulties, developmental delays.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn Error of Metabolism: Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and developmental delays. Key symptom not reported: seizures.

+2. Inborn Error of Metabolism: Tyrosinemia: Consistent with hypertyrosinemia, developmental delays, and potential liver involvement (neonatal death). Key symptoms not reported: liver dysfunction, renal tubular dysfunction.

+3. Congenital Muscular Dystrophy or Myopathy: Consistent with generalized hypotonia, motor delay, and prenatal abnormalities. Key symptoms not reported: progressive muscle weakness, respiratory involvement.

+4. Chromosomal Abnormality or Genetic Syndrome: Consistent with a broad range of symptoms, including developmental delays, hypotonia, congenital malformations, and early mortality. Additional information on specific dysmorphic features or genetic testing results could help narrow down the diagnosis.

+5. Neurodegenerative Disorder or Brain Malformation: Consistent with motor delays, hypotonia, and potential neurological involvement (early mortality). Key symptoms not reported: specific neurological deficits, seizures, or brain imaging findings.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn Error of Metabolism: Consistent with hypertyrosinemia, hyperphenylalaninemia, seizures, and developmental abnormalities. May not explain all symptoms like retrognathia or opisthotonus.

+2. Chromosomal Abnormality or Genetic Syndrome: Consistent with abnormalities of prenatal development, hypotonia, seizures, and respiratory issues. Specific syndrome would depend on genetic testing results.

+3. Congenital Myopathy or Neuromuscular Disorder: Consistent with hypotonia, respiratory issues (apnea), and potential for developmental delays. May not explain all symptoms like hypertyrosinemia or opisthotonus.

+4. Severe Congenital Malformation or Birth Injury: Consistent with abnormalities of prenatal development and potential for neurological and respiratory issues. May not explain metabolic abnormalities or specific symptoms like opisthotonus.

+5. Severe Perinatal Asphyxia or Hypoxic-Ischemic Encephalopathy: Consistent with potential for developmental delays, seizures, and respiratory issues. May not explain metabolic abnormalities or specific symptoms like retrognathia or opisthotonus.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1. Tyrosinemia: Consistent with hypertyrosinemia, elevated alkaline phosphatase and alpha-fetoprotein, liver dysfunction, neurological symptoms (autistic behavior, intellectual disability, seizures), and potential for early death. Key symptoms not reported: liver failure, kidney dysfunction, rickets.

+2. Mitochondrial disorder: Matches the combination of neurological symptoms (autistic behavior, intellectual disability, seizures, motor delay), metabolic abnormalities, and potential for early death. Key symptoms not reported depend on the specific disorder.

+3. Maple syrup urine disease (MSUD): Fits elevated branched-chain amino acids (abnormal aspartate family amino acid concentration), neurological symptoms (autistic behavior, intellectual disability, seizures), and potential for early death. Key symptoms not reported: maple syrup odor, poor feeding, lethargy.

+4. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, intellectual disability, autistic behavior, and seizures. Key symptoms not reported: musty odor, fair skin and hair, eczema.

+5. Lesch-Nyhan syndrome: Matches self-mutilation, intellectual disability, hyperactivity, and neurological symptoms. Key symptoms not reported: gouty arthritis, compulsive lip/finger biting, aggressive behavior.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Galactosemia: Consistent with hypergalactosemia, vomiting, increased total bilirubin, and potentially death in infancy if left untreated.
+2. Biliary atresia: Consistent with increased total bilirubin and vomiting, but does not explain hypergalactosemia.
+3. Neonatal hepatitis: Consistent with increased total bilirubin and vomiting, but does not explain hypergalactosemia or death in infancy.
+4. Inborn error of metabolism: A broad category of inherited metabolic disorders that could potentially explain the combination of symptoms, including hypergalactosemia and increased bilirubin levels.
+5. Congenital liver disease: A general term for various liver disorders present at birth, which could account for the increased bilirubin levels and potentially death in infancy, but does not specifically explain the hypergalactosemia symptom.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, abnormal tyrosine levels, and potential developmental abnormalities if untreated.

+2. Maple syrup urine disease: An inborn error of metabolism causing elevated branched-chain amino acids, which can lead to developmental issues and neonatal death if severe.

+3. Trisomy 18 (Edwards syndrome): A chromosomal abnormality causing multiple congenital malformations, developmental delays, and a high risk of neonatal death.

+4. Congenital cytomegalovirus infection: A viral infection during pregnancy that can cause various birth defects, developmental delays, and potentially neonatal death in severe cases.

+5. Zellweger syndrome: A peroxisomal disorder that can cause developmental abnormalities, hypotonia, and potentially early death due to liver dysfunction or respiratory issues.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Carnitine deficiency disorders: Consistent with abnormal circulating carnitine concentration and early death. Key symptom not reported: metabolic crises, hypoglycemia, cardiomyopathy.

+2. Fatty acid oxidation disorders: Consistent with obesity, abnormal carnitine concentration, and early death. Key symptoms not reported: hypoglycemia, metabolic crises, liver dysfunction.

+3. Organic acidemias: Consistent with obesity, abnormal carnitine concentration, and early death. Key symptoms not reported: metabolic crises, developmental delays, seizures.

+4. Lysosomal storage diseases: Consistent with obesity, abnormal carnitine concentration, and early death. Key symptoms not reported: organomegaly, skeletal abnormalities, neurological deficits.

+5. Congenital heart defects: Consistent with early death. Key symptoms not reported: cyanosis, heart murmurs, respiratory distress.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and intellectual disability. May not explain all symptoms, such as prenatal abnormalities or early death.

+2. Tyrosinemia: Consistent with hypertyrosinemia, intellectual disability, and potential for liver dysfunction leading to early death. May not explain prenatal abnormalities.

+3. Chromosomal abnormality or genetic syndrome: Could account for prenatal/birth abnormalities, intellectual disability, and potential for early death. Specific syndrome would depend on additional clinical and genetic testing.

+4. Congenital malformation or birth defect: Consistent with abnormality of prenatal development or birth, and could potentially lead to early death. May not explain metabolic abnormalities or intellectual disability.

+5. Severe perinatal infection or injury: Could potentially cause prenatal/birth abnormalities, intellectual disability, and early death. May not explain metabolic abnormalities.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with microcephaly, intellectual disability, syndactyly, hypotonia, elevated 7-dehydrocholesterol and 8-dehydrocholesterol levels. May not fully explain respiratory issues or recurrent infections.

+2. Lathosterolosis: Consistent with elevated 7-dehydrocholesterol and 8-dehydrocholesterol levels, developmental delays, and congenital anomalies. May not account for all symptoms.

+3. Congenital disorder of glycosylation (CDG): Consistent with developmental delays, hypotonia, multisystem involvement. Specific subtype would need to be determined based on further testing.

+4. Mitochondrial disorder: Consistent with multisystem involvement, developmental delays, hypotonia, gastrointestinal issues, and potential metabolic abnormalities. Specific disorder would need to be identified through genetic testing and metabolic workup.

+5. Chromosomal abnormality or contiguous gene deletion syndrome: Consistent with the presence of multiple congenital anomalies, developmental delays, and multisystem involvement. Specific syndrome would need to be identified through genetic testing and clinical evaluation.",Hereditary metabolic disorders
['Canavan disease'],"+1. Lysosomal storage disorder: Consistent with hypotonia, cerebral atrophy, abnormal amino acid levels, and potentially strabismus and obesity in some types. Key symptoms not reported: organomegaly, skeletal abnormalities.

+2. Mitochondrial disorder: Consistent with hypotonia, cerebral atrophy, and potentially abnormal amino acid levels. Key symptoms not reported: seizures, lactic acidosis, muscle weakness.

+3. Leukodystrophy: Consistent with cerebral atrophy, hypotonia, and potentially abnormal amino acid levels. Key symptoms not reported: progressive neurological decline, vision/hearing loss.

+4. Congenital disorder of glycosylation (CDG): Consistent with hypotonia, strabismus, and potentially abnormal amino acid levels. Key symptoms not reported: developmental delay, coagulopathy, liver dysfunction.

+5. Prader-Willi syndrome: Consistent with hypotonia, obesity, and potentially abnormal amino acid levels. Key symptoms not reported: characteristic facial features, intellectual disability, hypogonadism.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Congenital heart defect: Consistent with coarctation of the aorta and potential early mortality. Other common symptoms like cyanosis or heart murmurs were not reported.

+2. Metabolic disorder (e.g., tyrosinemia, phenylketonuria): Consistent with hypertyrosinemia and hyperphenylalaninemia. Symptoms like developmental delays or neurological issues were not reported.

+3. Genetic syndrome: Could explain the combination of obesity, congenital defects, and metabolic abnormalities. Additional details about dysmorphic features or developmental delays would be helpful.

+4. Severe infection: Consistent with fever and pneumonia, but the early mortality and other symptoms suggest an underlying condition.

+5. Endocrine disorder: Obesity could be a symptom, but the early mortality and other symptoms are not typical of most endocrine disorders alone.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria: Consistent with hyperhomocystinemia, hypermethioninemia, and aminoaciduria. May also present with developmental delays and other complications.

+2. Methylmalonic acidemia: Consistent with aminoaciduria and potential neonatal complications. Elevated methylmalonic acid levels (not reported) are a key symptom.

+3. Maple syrup urine disease: Consistent with aminoaciduria and potential neonatal complications. Characteristic maple syrup odor (not reported) is a key symptom.

+4. Trisomy 13 (Patau syndrome): Consistent with abnormalities of prenatal development or birth and potential neonatal/childhood death. Other characteristic features (e.g., congenital malformations) not reported.

+5. Trisomy 18 (Edwards syndrome): Consistent with abnormalities of prenatal development or birth and potential neonatal/childhood death. Other characteristic features (e.g., congenital malformations) not reported.",Hereditary metabolic disorders
[],"+1. Hereditary orotic aciduria: Consistent with ataxia, generalized hypotonia, abnormal circulating pyrimidine concentration, and uraciluria. May also involve developmental delay and failure to thrive.

+2. Lesch-Nyhan syndrome: Consistent with ataxia, generalized hypotonia, and uraciluria. Typically also involves self-mutilating behavior and cognitive impairment, which are not mentioned.

+3. Mitochondrial disorder: Consistent with ataxia, generalized hypotonia, and potential metabolic abnormalities. Specific symptoms can vary widely depending on the type of mitochondrial disorder.

+4. Spinal muscular atrophy (SMA): Consistent with ataxia and generalized hypotonia. Does not typically involve metabolic abnormalities or early childhood death.

+5. Cerebral palsy: Consistent with ataxia and generalized hypotonia. Does not typically involve metabolic abnormalities or early childhood death.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia and potential for early death if untreated. Key symptoms not reported: liver disease, neurological problems.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Key symptoms not reported: intellectual disability, seizures.

+3. Maple syrup urine disease (MSUD): Consistent with potential for elevated tyrosine and phenylalanine levels, and early death if untreated. Key symptoms not reported: maple syrup odor in urine, neurological problems.

+4. Homocystinuria: Consistent with potential for intellectual disability and early death if untreated. Key symptoms not reported: skeletal abnormalities, thrombosis.

+5. Alkaptonuria: Consistent with hypertyrosinemia. Key symptoms not reported: darkening of urine and connective tissues.",Hereditary metabolic disorders
[],"+1. Pyrimidine metabolic disorder: Consistent with abnormal circulating pyrimidine concentration, uraciluria, and potentially contributing to respiratory insufficiency and early death.

+2. Severe congenital lung malformation: Consistent with respiratory insufficiency and potentially leading to early death. No specific symptoms related to pyrimidine metabolism reported.

+3. Mitochondrial disorder: Consistent with multi-organ involvement, respiratory insufficiency, and potentially contributing to early death. No specific symptoms related to pyrimidine metabolism reported.

+4. Neuromuscular disorder affecting respiration: Consistent with respiratory insufficiency and potentially contributing to early death. No specific symptoms related to pyrimidine metabolism reported.

+5. Organic acidemia: Consistent with multi-organ involvement, respiratory insufficiency, and potentially contributing to early death. No specific symptoms related to pyrimidine metabolism reported.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1. Biliary atresia: Consistent with ascites, hypoalbuminemia, hypoproteinemia, elevated alkaline phosphatase and alpha-fetoprotein levels. May not explain all symptoms like hypertyrosinemia and aminoaciduria.

+2. Tyrosinemia: Consistent with hypertyrosinemia, aminoaciduria, elevated alkaline phosphatase and alpha-fetoprotein levels, and liver dysfunction. May not account for ascites or hematological abnormalities.

+3. Congenital hemolytic anemia: Consistent with pallor, anemia, and thrombocytosis. May not explain liver involvement or metabolic abnormalities.

+4. Glycogen storage disease: Consistent with liver dysfunction, elevated alkaline phosphatase and alpha-fetoprotein levels, and potentially aminoaciduria. May not explain ascites or hematological findings.

+5. Malabsorption disorder: Consistent with hypoalbuminemia, hypoproteinemia, and potentially ascites. May not account for metabolic abnormalities or hematological findings.",Hereditary metabolic disorders
['Canavan disease'],"+1. Maple syrup urine disease (MSUD): Consistent with seizures, motor delay, and abnormal circulating aspartate family amino acid concentration. Typically presents in infancy with a distinctive maple syrup odor (not reported).

+2. Phenylketonuria (PKU): Consistent with seizures, motor delay, and abnormal circulating aspartate family amino acid concentration. Often detected through newborn screening (not mentioned).

+3. Leigh syndrome: A severe neurometabolic disorder that could explain seizures, motor delay, and potential death in infancy. May involve abnormal amino acid levels (not specified).

+4. Zellweger syndrome: A peroxisomal disorder that can cause seizures, motor delays, and early death. Abnormal amino acid levels are possible but not a defining feature.

+5. Lissencephaly: A rare brain malformation that could lead to seizures, motor delays, and potentially early death. Amino acid abnormalities are not typically associated with this condition.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Glycine encephalopathy (non-ketotic hyperglycinemia): Consistent with abnormal glycine levels, gastrointestinal symptoms, and recurrent infections. May not explain body odor.

+2. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with gastrointestinal symptoms, abnormal metabolite levels, and body odor. May not fully explain recurrent viral infections.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections. Does not typically cause gastrointestinal symptoms or abnormal metabolite levels.

+4. Inflammatory bowel disease (IBD): Consistent with gastrointestinal inflammation, diarrhea, and abdominal pain. Does not explain abnormal metabolite levels or recurrent viral infections.

+5. Metabolic disorder involving fatty acid metabolism: Consistent with abnormal carnitine levels, gastrointestinal symptoms, and body odor. May not fully explain recurrent viral infections or death in infancy/childhood.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, intellectual disability. Key symptom not reported: fair skin, light hair, and blue eyes.

+2. Tyrosinemia: Hypertyrosinemia, intellectual disability, elevated urinary carboxylic acid. Key symptoms not reported: liver dysfunction, kidney dysfunction, rickets.

+3. Inborn error of metabolism: Intellectual disability, obesity, hypertyrosinemia, hyperphenylalaninemia, elevated urinary carboxylic acid. Specific disorder not identified.

+4. Genetic syndrome: Intellectual disability, obesity. Key symptoms not reported: specific dysmorphic features or organ involvement associated with the syndrome.

+5. Hypertensive disorder: Hypertension. Key symptoms not reported: specific organ involvement or complications related to hypertension.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Hyperalaninemia, abnormal carnitine levels, developmental abnormalities, and early death are consistent with certain IEMs. Key symptoms not reported: specific metabolic derangements, acidosis, or other organ involvement depending on the disorder.

+2. Chromosomal abnormality or genetic syndrome: Prenatal developmental abnormalities, small for gestational age, and severe hearing impairment could be explained by chromosomal or genetic conditions. Key symptoms not reported: specific dysmorphic features, congenital anomalies, or other associated findings.

+3. Congenital infection (TORCH): Abnormal prenatal development, growth restriction, and hearing loss may result from intrauterine infections like cytomegalovirus, rubella, or toxoplasmosis. Key symptoms not reported: specific clinical features of the causative infection.

+4. Perinatal asphyxia or hypoxic-ischemic encephalopathy: Severe perinatal insult could lead to developmental delays, growth restriction, and early death. Key symptoms not reported: specific neurological deficits or imaging findings.

+5. Mitochondrial disorder: Abnormal prenatal development, hearing loss, and early death may be seen in mitochondrial diseases. Key symptoms not reported: specific metabolic derangements, organ involvement, or neurological manifestations.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with lethargy, drowsiness, and abnormal circulating ornithine concentration. Key symptom not reported: Hyperammonemia.

+2. Mitochondrial disorder: Consistent with lethargy, drowsiness, sleep abnormality, and potential metabolic abnormalities. Key symptoms not reported: Muscle weakness, seizures, developmental delays.

+3. Organic acidemia: Consistent with lethargy, drowsiness, and potential metabolic abnormalities (oroticaciduria). Key symptoms not reported: Vomiting, acidosis, failure to thrive.

+4. Fatty acid oxidation disorder: Consistent with lethargy, drowsiness, and potential metabolic abnormalities. Key symptoms not reported: Hypoglycemia, liver dysfunction, cardiomyopathy.

+5. Leigh syndrome: Consistent with lethargy, drowsiness, sleep abnormality. Key symptoms not reported: Ataxia, ophthalmoplegia, respiratory distress.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with ataxia, dystonia, abnormal cerebral morphology, glutaric aciduria, decreased plasma free carnitine, and potential death in childhood. May not fully explain abnormal myelination.

+2. Leukodystrophy (e.g., metachromatic leukodystrophy, Krabbe disease): Consistent with ataxia, dystonia, abnormal cerebral morphology, and abnormal myelination. Does not typically involve glutaric aciduria or decreased plasma free carnitine.

+3. Mitochondrial disorder (e.g., Leigh syndrome, MELAS): Consistent with ataxia, dystonia, abnormal cerebral morphology, and potential death in childhood. Does not typically involve glutaric aciduria or decreased plasma free carnitine.

+4. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with ataxia, dystonia, abnormal cerebral morphology, and potential metabolic abnormalities. May not fully explain abnormal myelination or decreased plasma free carnitine.

+5. Peroxisomal disorder (e.g., Zellweger syndrome): Consistent with ataxia, dystonia, abnormal cerebral morphology, and potential metabolic abnormalities. May not fully explain glutaric aciduria or decreased plasma free carnitine.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, a key symptom of this genetic disorder that impairs phenylalanine metabolism. Neonatal death can occur if left untreated.

+2. Maple syrup urine disease: An inborn error of metabolism that can cause hyperphenylalaninemia, along with other metabolic abnormalities. Severe cases can lead to neonatal death.

+3. Organic acidemias: A group of metabolic disorders that can cause hyperphenylalaninemia and other metabolic imbalances, potentially leading to neonatal death in severe cases.

+4. Congenital malformations: Severe congenital abnormalities or malformations could potentially explain neonatal death, although the hyperphenylalaninemia symptom suggests a metabolic disorder is more likely.

+5. Chromosomal abnormalities: Certain chromosomal disorders, such as trisomies or deletions, can be associated with neonatal death, but the hyperphenylalaninemia symptom is not typically seen in these conditions.",Hereditary metabolic disorders
['Systemic primary carnitine deficiency'],"+1. Organic acidemia: Consistent with encephalopathy, hypotonia, cardiomyopathy, hypoglycemia, vomiting, abnormal amino acid and carnitine levels. May not explain hepatomegaly or elevated transaminases.

+2. Mitochondrial disorder: Matches encephalopathy, cardiomyopathy, hypoglycemia, anemia, and multi-system involvement. May not account for hepatomegaly or elevated transaminases.

+3. Lysosomal storage disorder: Consistent with hepatomegaly, neurological symptoms, and metabolic abnormalities. May not explain cardiomyopathy or hypoglycemia.

+4. Acute liver failure or inborn error of metabolism affecting the liver: Explains hepatomegaly, elevated transaminases, vomiting, and metabolic disturbances. May not account for cardiomyopathy or neurological symptoms.

+5. Genetic syndrome or chromosomal abnormality: Could potentially explain the multi-system involvement and severe presentation. Specific symptoms may vary depending on the underlying condition.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Joubert syndrome: Consistent with ataxia, nystagmus, hypotonia, motor delay, cerebellar agenesis, and developmental delays. Key symptoms not reported: breathing abnormalities, kidney or liver involvement.

+2. Pontocerebellar hypoplasia: Consistent with ataxia, nystagmus, hypotonia, motor delay, cerebellar atrophy/agenesis, and developmental delays. Key symptoms not reported: progressive microcephaly, seizures.

+3. Leukodystrophy (e.g., Pelizaeus-Merzbacher disease): Consistent with ataxia, hypotonia, motor delay, encephalopathy, and developmental delays. Key symptoms not reported: visual or hearing impairments, spasticity.

+4. Ataxia-telangiectasia: Consistent with ataxia, nystagmus, and cerebellar atrophy. Key symptoms not reported: telangiectasias, immunodeficiency.

+5. Congenital disorder of glycosylation: Consistent with ataxia, hypotonia, encephalopathy, and developmental delays. Key symptoms not reported: dysmorphic features, coagulopathy, protein-losing enteropathy.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria: Consistent with ectopia lentis, intellectual disability, hyperhomocystinemia, hypermethioninemia, and aminoaciduria. May not cause death in infancy or childhood if treated.

+2. Maple syrup urine disease (MSUD): Consistent with intellectual disability, delayed speech and language development, and abnormal amino acid levels. Does not typically cause ectopia lentis or myopia.

+3. Glutaric aciduria type 1: Consistent with intellectual disability, delayed development, and dyskinesia. Does not typically cause ectopia lentis or vision problems.

+4. Methylmalonic acidemia: Consistent with intellectual disability, developmental delays, and metabolic abnormalities. Does not typically cause ectopia lentis or vision problems.

+5. Congenital disorder of glycosylation: Consistent with intellectual disability, developmental delays, and multisystem involvement. May cause aminoaciduria and other metabolic abnormalities, but specific symptoms can vary.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, metabolic acidosis, lethargy, seizures, and potential early death. Key symptoms not reported: vomiting, protein avoidance.

+2. Leukodystrophy (e.g., Krabbe disease): Consistent with seizures, ataxia, hyperreflexia, and potential early death. Key metabolic abnormalities not reported.

+3. Mitochondrial disorder (e.g., Leigh syndrome): Consistent with neurological symptoms, metabolic acidosis, and potential early death. Hyperammonemia not typically seen.

+4. Neurodegenerative disorder (e.g., late infantile neuronal ceroid lipofuscinosis): Consistent with seizures, ataxia, sleep abnormalities, and potential early death. Metabolic abnormalities not typical.

+5. Metabolic disorder (unspecified): Consistent with metabolic acidosis, hyperammonemia, oroticaciduria, and potential early death. Specific neurological symptoms not fully explained.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Microcephaly, intellectual disability, syndactyly, hypotonia, ataxia, hyperreflexia, failure to thrive, hypocholesterolemia, elevated 8-dehydrocholesterol. Key symptoms not reported: cleft palate, genital abnormalities.

+2. Zellweger spectrum disorders (ZSDs): Microcephaly, intellectual disability, hypotonia, ataxia, hyperreflexia, failure to thrive, feeding difficulties, fatigue. Cholesterol abnormalities not typical.

+3. Congenital disorders of glycosylation (CDGs): Intellectual disability, hypotonia, failure to thrive, feeding difficulties, fatigue. Physical abnormalities and cholesterol abnormalities less common.

+4. Mitochondrial disorders: Intellectual disability, hypotonia, ataxia, hyperreflexia, failure to thrive, feeding difficulties, fatigue. Cholesterol abnormalities and specific physical features less likely.

+5. Chromosomal abnormalities or genetic syndromes: Microcephaly, intellectual disability, syndactyly, strabismus, ptosis, hypotonia, ataxia, hyperreflexia, failure to thrive. Cholesterol abnormalities not typical.",Hereditary metabolic disorders
['Glycogen storage disease due to glycogen debranching enzyme deficiency'],"+1. Mitochondrial myopathy: Generalized hypotonia, increased circulating lactate concentration, abnormal circulating amino acid levels, increased lactate dehydrogenase and creatine kinase concentrations. Key symptom not reported: Exercise intolerance.

+2. Fatty acid oxidation disorder: Hypertriglyceridemia, hepatomegaly, increased circulating lactate concentration, neonatal death. Key symptom not reported: Hypoglycemia.

+3. Organic acidemia: Abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, increased circulating lactate concentration, neonatal death. Key symptom not reported: Metabolic acidosis.

+4. Glycogen storage disease: Generalized hypotonia, hepatomegaly, increased circulating lactate concentration. Key symptoms not reported: Failure to thrive, muscle cramps.

+5. Mitochondrial depletion syndrome: Generalized hypotonia, increased circulating lactate concentration, neonatal death. Key symptoms not reported: Neurological abnormalities, seizures.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with glutaric aciduria, abnormal acylcarnitine levels, hypotonia, and potential for early death. Microcephaly and cerebral atrophy are less common.

+2. Leigh syndrome: Matches microcephaly, hypotonia, athetosis, cerebral cortical atrophy, and potential for death in infancy or early childhood. Metabolic abnormalities may or may not be present.

+3. Leukodystrophies (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with microcephaly, hypotonia, athetosis, cerebral cortical atrophy, and potential for early death. Metabolic abnormalities may or may not be present.

+4. Mitochondrial disorders: Can present with a combination of neurological (microcephaly, hypotonia, athetosis, cerebral atrophy), muscular (hypotonia), and metabolic (glutaric aciduria, abnormal acylcarnitine levels) symptoms, as well as potential for early mortality.

+5. Cerebral palsy: Matches hypotonia, athetosis, and potential for developmental delays. However, metabolic abnormalities and early mortality are not typical features.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Non-ketotic hyperglycinemia (NKH): Consistent with hyperglycinemia, hyperglycinuria, hyperammonemia, and potential death in infancy/childhood. May not explain hyperalaninemia or ichthyosis.

+2. Organic acidemia: Consistent with elevated urinary carboxylic acid, hyperammonemia, and potential death in infancy/childhood. May not explain hyperglycinemia or ichthyosis.

+3. Disorder of amino acid metabolism: Consistent with hyperalaninemia, hyperammonemia, and abnormal circulating glutamine/carnitine concentrations. May not explain hyperglycinemia or ichthyosis.

+4. Fatty acid oxidation disorder: Consistent with abnormal circulating carnitine concentrations, hyperammonemia, and potential death in infancy/childhood. May not explain hyperglycinemia or ichthyosis.

+5. Inherited metabolic disorder with ichthyosis: Consistent with ichthyosis and potential death in infancy/childhood. May not explain the specific metabolic abnormalities reported.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Zellweger syndrome: Consistent with intellectual disability, motor delay, abnormal facial shape, abnormal calvaria morphology, death in childhood, and abnormal organic acid levels. Key symptom not reported: seizures.

+2. Glutaric aciduria type 1: Consistent with intellectual disability, motor delay, abnormal calvaria morphology (macrocephaly), and elevated urinary carboxylic acid. Key symptom not reported: acute encephalopathic crises.

+3. Methylmalonic acidemia: Consistent with intellectual disability, motor delay, abnormal circulating monocarboxylic acid concentration, and elevated urinary carboxylic acid. Key symptom not reported: metabolic acidosis.

+4. Craniofacial dysostosis: Consistent with abnormal facial shape and abnormal calvaria morphology. However, does not fully explain the intellectual disability, motor delay, and metabolic abnormalities.

+5. Chromosomal abnormality (e.g., trisomy 18 or 13): Consistent with intellectual disability, motor delay, abnormal facial shape, and abnormal calvaria morphology. However, does not directly explain the metabolic abnormalities.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Galactosemia: Consistent with abnormality of galactoside metabolism, hypergalactosemia, liver dysfunction (hepatic failure, increased bilirubin), and potential for severe complications if untreated (neonatal death, death in infancy/childhood).

+2. Inborn error of metabolism (amino acid disorder or organic acidemia): Matches abnormal circulating aspartate family amino acid and alanine concentrations, as well as potential for liver dysfunction, developmental delays, and early mortality.

+3. Genetic syndrome or chromosomal abnormality: Could explain the combination of intellectual disability, motor delay, delayed speech/language development, and potential organ involvement (hepatic failure).

+4. Liver disease or hepatic failure of unknown etiology: Consistent with hepatic failure, increased bilirubin, prolonged partial thromboplastin time, and potential for severe complications.

+5. Prematurity complications: Premature birth, along with potential for developmental delays, liver dysfunction, and early mortality, could suggest complications related to prematurity.",Hereditary metabolic disorders
['Neonatal intrahepatic cholestasis due to citrin deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, aminoaciduria, elevated citrulline, and potential abnormalities of prenatal development/neonatal death. Key symptoms not reported: vomiting, lethargy, seizures.

+2. Organic acidemia: Consistent with hyperammonemia, aminoaciduria, and potential abnormalities of prenatal development/neonatal death. Key symptoms not reported: metabolic acidosis, ketosis, vomiting.

+3. Liver disease: Consistent with hyperammonemia and potential abnormalities of prenatal development/neonatal death. Key symptoms not reported: jaundice, ascites, coagulopathy.

+4. Phenylketonuria (PKU): Consistent with aminoaciduria and abnormal proline levels. Key symptoms not reported: developmental delays, musty odor, fair skin and hair.

+5. Maple syrup urine disease (MSUD): Consistent with aminoaciduria and abnormal proline levels. Key symptoms not reported: maple syrup odor, lethargy, seizures.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid, hypertyrosinemia, hyperphenylalaninemia. May also explain recurrent infections and early mortality.

+2. Urea cycle disorder: Matches hypertyrosinemia, hyperphenylalaninemia, and potentially early mortality. Recurrent infections and other metabolic abnormalities may be secondary effects.

+3. Severe combined immunodeficiency (SCID): Aligns with recurrent viral infections and potentially early mortality. Metabolic abnormalities could be secondary effects.

+4. Porphyria: Consistent with abnormal circulating porphyrin concentration, and may explain other metabolic disturbances. Recurrent infections and early mortality are possible complications.

+5. Iron overload disorder: Matches decreased circulating ferritin concentration, but does not fully explain the other symptoms reported.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with lethargy, hypotonia, tremor, abnormal circulating leucine concentration, elevated urinary carboxylic acid, and body odor. Key symptom not reported: maple syrup odor in urine and cerumen.

+2. Leigh syndrome: Consistent with lethargy, hypotonia, tremor, opisthotonus, drowsiness, and death in infancy. Key symptoms not reported: respiratory abnormalities, lactic acidosis, and brain lesions on imaging.

+3. Infantile neuroaxonal dystrophy: Consistent with hypotonia, tremor, and death in infancy. Key symptoms not reported: psychomotor regression, seizures, and optic atrophy.

+4. Nonketotic hyperglycinemia: Consistent with lethargy, hypotonia, and tremor. Key symptoms not reported: elevated glycine levels and seizures.

+5. Mitochondrial encephalomyopathy: Consistent with lethargy, hypotonia, tremor, and death in infancy. Key symptoms not reported: lactic acidosis, seizures, and specific neuroimaging findings.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism (e.g., phenylketonuria, tyrosinemia): Consistent with hypertyrosinemia, hyperphenylalaninemia, hypotonia, and potential developmental delays.

+2. Iron deficiency anemia: Consistent with anemia, decreased circulating ferritin and iron concentrations, and potential prematurity complications.

+3. Prematurity complications: Consistent with premature birth, hypotonia, anemia, and potential metabolic abnormalities.

+4. Congenital myopathy: Consistent with generalized hypotonia and potential muscle weakness or developmental delays.

+5. Vitamin D deficiency or metabolic disorder: Consistent with abnormality of vitamin D metabolism, which can affect muscle tone and bone health.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with hypertelorism, anteverted nares, syndactyly, intellectual disability, delayed speech and language development, seizures, motor delay, abnormal foot morphology, hypocholesterolemia, elevated 8-dehydrocholesterol, and elevated circulating 7-dehydrocholesterol concentration. May also explain death in infancy/childhood in severe cases.

+2. Autism spectrum disorder (ASD): Consistent with intellectual disability, delayed speech and language development, hyperactivity, and self-mutilation. Does not account for physical and metabolic symptoms.

+3. Fetal alcohol syndrome (FAS): Consistent with intellectual disability, delayed development, hypertelorism, and abnormal facial features (anteverted nares). Does not explain metabolic symptoms or syndactyly.

+4. Rett syndrome: Consistent with intellectual disability, motor delays, seizures, and self-mutilation. Does not typically involve physical and metabolic symptoms.

+5. Congenital disorders of glycosylation (CDG): Consistent with intellectual disability, seizures, and developmental delays. May not fully account for physical and cholesterol-related symptoms.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with microcephaly, developmental delays, failure to thrive, metabolic acidosis, hyperammonemia, methylmalonic aciduria, and elevated homocysteine levels. Key symptoms not reported: recurrent vomiting and lethargy.

+2. Propionic acidemia: Matches many symptoms, including developmental delays, metabolic acidosis, hyperammonemia, and elevated organic acids. May not fully explain the microcephaly and severe growth impairment.

+3. Urea cycle disorder: Consistent with hyperammonemia, developmental delays, and metabolic decompensation. May not account for the specific organic aciduria and hyperglycinemia observed.

+4. Mitochondrial disorder: Could explain the multi-system involvement, including neurological, metabolic, and organ dysfunction. Specific genetic or biochemical testing would be needed to confirm.

+5. Congenital infection: Certain infections during pregnancy can cause developmental delays, growth impairment, and organ damage. However, the metabolic abnormalities and organic aciduria are less typical of this diagnosis.",Hereditary metabolic disorders
[],"+1. Lesch-Nyhan syndrome: Consistent with ataxia, hypotonia, lethargy, sleep abnormality, abnormal pyrimidine concentration, and uraciluria. May not cause death in infancy.

+2. Mitochondrial disorder: Consistent with ataxia, lethargy, hypotonia, sleep abnormality, and drowsiness. Uraciluria and abnormal pyrimidine concentration are less common features.

+3. Inborn error of pyrimidine metabolism: Consistent with abnormal pyrimidine concentration and uraciluria. Neurological symptoms like ataxia, hypotonia, lethargy, and sleep abnormalities may or may not be present, depending on the specific disorder.

+4. Leukodystrophy: Consistent with ataxia, hypotonia, lethargy, and sleep abnormalities. Does not typically involve abnormal pyrimidine metabolism or uraciluria.

+5. Neuronal ceroid lipofuscinosis: Consistent with ataxia, hypotonia, lethargy, sleep abnormalities, and potential death in infancy. Does not typically involve abnormal pyrimidine metabolism or uraciluria.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Inborn error of metabolism (IEM): Consistent with abnormality of prenatal development, death in infancy/childhood, hyperammonemia, and abnormal glycine/carnitine levels. Common symptoms of IEMs include developmental delays, seizures, and metabolic crises.

+2. Urea cycle disorder: Consistent with hyperammonemia and abnormal glycine levels. Key symptoms include lethargy, vomiting, and respiratory distress, which were not reported.

+3. Glycine encephalopathy: Consistent with abnormal glycine levels and developmental abnormalities. Patients may also experience seizures and respiratory failure, which were not mentioned.

+4. Mitochondrial disorder: Consistent with abnormal carnitine levels and potential metabolic decompensation. Other symptoms like muscle weakness, seizures, and developmental delays may be present but were not reported.

+5. Fatty acid oxidation defect: Consistent with abnormal carnitine levels and potential metabolic crises. Patients may also experience hypoglycemia, liver dysfunction, and cardiomyopathy, which were not reported.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Organic acidemia: Consistent with seizures, hypotonia, elevated urinary carboxylic acid, and potential for early death. Key symptoms not reported: metabolic acidosis, vomiting, lethargy.

+2. Leigh syndrome: Consistent with seizures, hypotonia, and potential for early death. Key symptom not reported: characteristic brain lesions on MRI.

+3. Spinal muscular atrophy: Consistent with hypotonia and potentially seizures. Key symptoms not reported: progressive muscle weakness, respiratory difficulties.

+4. Cerebral palsy: Consistent with seizures and hypotonia. Key symptoms not reported: abnormal muscle tone, movement disorders, developmental delays.

+5. Mitochondrial disorder: Consistent with seizures, hypotonia, and potential for early death. Key symptom not reported: lactic acidosis.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Consistent with decreased enzyme levels, carnitine deficiency, developmental delays, and potential early mortality. Key symptoms not reported may include specific metabolic abnormalities or organ involvement.

+2. Chromosomal abnormality or genetic syndrome: Consistent with abnormality of prenatal development or birth, developmental delays, and potential early mortality. Key symptoms not reported may include specific physical features or organ involvement.

+3. Congenital malformation or birth defect: Consistent with abnormality of prenatal development or birth, and potential early mortality. Key symptoms not reported may include specific structural abnormalities or organ involvement.

+4. Neurodevelopmental disorder: Consistent with delayed speech and language development. Key symptoms not reported may include specific behavioral or cognitive impairments.

+5. Perinatal or neonatal complication: Consistent with abnormality of prenatal development or birth, and potential early mortality. Key symptoms not reported may include specific complications during pregnancy, delivery, or neonatal period.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, metabolic acidosis, seizures, and neurological symptoms. Typical body odor not reported.

+2. Cerebral palsy: Consistent with spastic diplegia, spastic tetraplegia, motor delay, generalized hypotonia, and seizures. Does not explain metabolic abnormalities.

+3. Mitochondrial disorder: Could potentially explain both neurological symptoms (seizures, hypotonia, motor delay) and metabolic acidosis. Specific symptoms may vary.

+4. Amino acid metabolism disorder: Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, metabolic acidosis, and potentially neurological symptoms. Specific disorder would need further testing.

+5. Genetic disorder affecting brain development: Could account for neurological symptoms (seizures, motor delays, hypotonia) and potentially metabolic issues. Specific disorder would require genetic testing.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Organic acidemia: Consistent with hyperammonemia, hyperglycinemia, hyperalaninemia, increased blood urea nitrogen, elevated circulating creatinine concentration, elevated urinary carboxylic acid. May not explain all symptoms like psychosis or severe short stature.

+2. Urea cycle disorder: Consistent with hyperammonemia, increased blood urea nitrogen, elevated circulating creatinine concentration. May not explain all symptoms like psychosis, hyperglycinemia, or physical abnormalities.

+3. Lysosomal storage disorder: Consistent with intellectual disability, cerebral atrophy, abnormal circulating porphyrin and carnitine concentrations, severe short stature, kyphoscoliosis. May not explain all metabolic abnormalities or psychosis.

+4. Mitochondrial disorder: Consistent with cerebral atrophy, intellectual disability, psychosis, anemia, elevated urinary carboxylic acid. May not explain all metabolic abnormalities or physical abnormalities.

+5. Neurodegenerative disorder: Consistent with psychosis, intellectual disability, cerebral atrophy. Does not explain metabolic abnormalities or physical abnormalities.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. L-2-hydroxyglutaric aciduria: Consistent with intellectual disability, seizures, ataxia, tremors, and the presence of L-2-hydroxyglutaric aciduria.

+2. Leukodystrophy: Consistent with intellectual disability, seizures, ataxia, and tremors. May not explain the specific metabolic marker (L-2-hydroxyglutaric aciduria).

+3. Mitochondrial disorder: Consistent with intellectual disability, seizures, ataxia, tremors, and potential early childhood death. May not explain the specific metabolic marker.

+4. Inherited metabolic disorder: Consistent with intellectual disability, seizures, ataxia, tremors, and potential early childhood death. Specific disorder would depend on metabolic testing results.

+5. Neurodegenerative disorder: Consistent with intellectual disability, seizures, ataxia, and tremors. Early childhood onset and death make this less likely than the other options.",Hereditary metabolic disorders
['Canavan disease'],"+1. Amino acid metabolism disorder: Consistent with abnormal circulating aspartate family amino acid concentration and potentially leading to motor delay and death in infancy if untreated. Key symptoms like specific amino acid level abnormalities or related metabolic issues may not have been reported.

+2. Genetic disorder affecting neurological development: Consistent with motor delay and potentially fatal outcomes in infancy. Key symptoms like specific neurological or developmental abnormalities may not have been reported.

+3. Congenital brain or nervous system malformation: Consistent with motor delay and potentially life-threatening complications. Key symptoms like specific structural abnormalities or associated neurological deficits may not have been reported.

+4. Mitochondrial disorder: Consistent with motor delay and potentially fatal outcomes in infancy due to impaired energy production. Key symptoms like specific metabolic abnormalities or multi-system involvement may not have been reported.

+5. Severe perinatal insult or injury: Consistent with motor delay and potentially fatal outcomes in infancy due to brain damage or injury during pregnancy, birth, or early postnatal period. Key symptoms like specific neurological deficits or risk factors may not have been reported.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Urea cycle disorder: Consistent with hyperammonemia, elevated citrulline, and neonatal presentation. Key symptoms like protein intolerance or neurological symptoms may not be reported.

+2. Biliary atresia: Increased bilirubin and neonatal presentation fit, but hyperammonemia and elevated citrulline are less common.

+3. Organic acidemia: Hyperammonemia and neonatal onset are consistent, but elevated citrulline and increased bilirubin may not be typical.

+4. Fatty acid oxidation disorder: Hyperammonemia and neonatal presentation are possible, but elevated citrulline and increased bilirubin are less common.

+5. Neonatal hepatitis: Increased bilirubin and neonatal presentation fit, but hyperammonemia and elevated citrulline are less specific.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Organic acidemia: Consistent with metabolic acidosis, dicarboxylic aciduria, 3-methylglutaric aciduria, vomiting, lethargy, and potential early death. May not explain hyperammonemia or recurrent infections.

+2. Urea cycle disorder: Consistent with hyperammonemia, lethargy, recurrent infections, and potential early death. May not explain aciduria or hypoglycemia.

+3. Fatty acid oxidation disorder: Consistent with hypoglycemia, metabolic acidosis, lethargy, and potential early death. May not explain aciduria or hyperammonemia.

+4. Mitochondrial disorder: Consistent with metabolic acidosis, lethargy, neurological symptoms, and multi-organ involvement. May not explain aciduria or hyperammonemia.

+5. Glycogen storage disease: Consistent with hypoglycemia, hepatomegaly, and metabolic abnormalities. May not explain aciduria, hyperammonemia, or recurrent infections.",Hereditary metabolic disorders
['Cystinuria'],"+1. Lysosomal storage disorder: Consistent with seizures, splenomegaly, respiratory insufficiency, and potential death in infancy. Key symptom not reported: specific neurological or skeletal abnormalities depending on the type of disorder.

+2. Mitochondrial disorder: Consistent with seizures, respiratory insufficiency, and potential death in infancy. Key symptom not reported: specific neurological or muscular symptoms depending on the type of disorder.

+3. Leukodystrophy: Consistent with seizures, respiratory insufficiency, and potential death in infancy. Key symptom not reported: specific neurological or motor deficits depending on the type of disorder.

+4. Severe combined immunodeficiency (SCID): Consistent with respiratory insufficiency and potential death in infancy due to infections. Key symptoms not reported: recurrent infections, failure to thrive.

+5. Congenital heart defect: Consistent with respiratory insufficiency and potential death in infancy in severe cases. Key symptoms not reported: specific cardiac symptoms (e.g., murmur, cyanosis), failure to thrive.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with hyperammonemia, methylmalonic aciduria, and abnormal amino acid levels. Key symptom not reported: metabolic acidosis.

+2. Propionic acidemia: Consistent with hyperammonemia, metabolic aciduria, and abnormal amino acid levels. Key symptom not reported: ketoacidosis.

+3. Urea cycle disorder: Consistent with hyperammonemia, hypoproteinemia, and increased blood urea nitrogen. Key symptom not reported: respiratory alkalosis.

+4. Leukodystrophy: Consistent with intellectual disability, motor delay, and generalized hypotonia. Key symptoms not reported: specific neurological deficits or brain imaging findings.

+5. Primary immunodeficiency: Consistent with recurrent viral infections. Key symptoms not reported: specific immune function abnormalities or infections.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid, recurrent viral infections, and early mortality. Key symptoms not reported: specific metabolic abnormalities depending on the type of organic acidemia.

+2. Tyrosinemia: Consistent with hypertyrosinemia and elevated urinary carboxylic acid. Key symptoms not reported: specific manifestations depending on the type of tyrosinemia (e.g., liver disease, kidney disease, neurological symptoms).

+3. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Key symptoms not reported: intellectual disability, neurological problems, and other manifestations if untreated.

+4. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections. Key symptoms not reported: specific immunological abnormalities and lack of metabolic abnormalities.

+5. Combined metabolic and immunodeficiency disorder: Consistent with the combination of metabolic abnormalities (hypertyrosinemia, hyperphenylalaninemia, elevated urinary carboxylic acid) and recurrent viral infections. Specific diagnosis would require further testing.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, intellectual disability, and potential developmental abnormalities. Key symptom not reported: seizures.

+2. Tyrosinemia: Consistent with hypertyrosinemia, intellectual disability, and potential developmental abnormalities. Key symptoms not reported: liver dysfunction, rickets.

+3. Down syndrome: Consistent with intellectual disability, potential prenatal/birth abnormalities, and potential early mortality. Key symptoms not reported: characteristic facial features, congenital heart defects.

+4. Prader-Willi syndrome: Consistent with intellectual disability, obesity, and potential early mortality. Key symptoms not reported: hypotonia, hypogonadism, behavioral issues.

+5. Congenital malformation syndrome: Consistent with multiple congenital abnormalities, intellectual disability, and potential early mortality. Additional information needed to specify the syndrome.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with hyperammonemia, vomiting, abnormal bleeding, and abnormality of the coagulation cascade. May also present with lethargy, seizures, and coma.

+2. Citrullinemia: Consistent with hyperammonemia, vomiting, abnormal bleeding, and abnormality of the coagulation cascade. May also cause poor appetite, lethargy, and developmental delays.

+3. Severe liver disease or failure: Consistent with hyperammonemia, vomiting, abnormal bleeding, and abnormality of the coagulation cascade. May also present with jaundice, ascites, and encephalopathy.

+4. Hemophilia: Consistent with abnormal bleeding and abnormality of the coagulation cascade. However, does not explain hyperammonemia, vomiting, or oroticaciduria.

+5. Leukemia or other blood disorders: Consistent with abnormal bleeding and abnormality of the coagulation cascade. However, does not explain hyperammonemia, vomiting, or oroticaciduria.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. L-2-hydroxyglutaric aciduria: Consistent with L-2-hydroxyglutaric acidemia, intellectual disability, abnormal cerebral morphology, and abnormal myelination. May not explain hypotonia, hyperreflexia, or hyperammonemia.

+2. Urea cycle disorder: Consistent with hyperammonemia, intellectual disability, and abnormal cerebral morphology. Does not typically present with hypotonia, hyperreflexia, or abnormal myelination.

+3. Leukodystrophy: Consistent with intellectual disability, abnormal cerebral morphology, and abnormal myelination. Does not typically cause hyperammonemia or L-2-hydroxyglutaric acidemia.

+4. Mitochondrial disorder: Consistent with intellectual disability, hypotonia, hyperreflexia, and abnormal cerebral morphology. May not explain hyperammonemia or L-2-hydroxyglutaric acidemia.

+5. Neurodegenerative disorder: Consistent with intellectual disability, abnormal cerebral morphology, and abnormal myelination. Does not typically cause hyperammonemia or L-2-hydroxyglutaric acidemia.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Ataxia-telangiectasia: Consistent with intellectual disability, ataxia, and cerebellar atrophy. May also involve immunodeficiency and increased cancer risk, which were not reported.

+2. Joubert syndrome: Matches intellectual disability, ataxia, and cerebellar agenesis or hypoplasia. Other features like breathing abnormalities and eye movement disorders were not mentioned.

+3. Dandy-Walker malformation: Aligns with intellectual disability, ataxia, and cerebellar abnormalities. Hydrocephalus (fluid buildup in the brain) is a common feature but was not reported.

+4. Congenital disorder of glycosylation: Could explain intellectual disability, ataxia, and cerebellar involvement. Thromboembolism and stroke-like episodes may be related to vascular complications.

+5. Mitochondrial encephalomyopathy: Matches intellectual disability, ataxia, and potential stroke-like episodes. Specific features like seizures, muscle weakness, or vision/hearing loss were not reported.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, premature birth, and neonatal death. Key symptom not reported: liver and kidney failure.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, premature birth, and neonatal death. Key symptoms not reported: intellectual disability, seizures, and neurological problems.

+3. Maple syrup urine disease (MSUD): Consistent with premature birth and neonatal death. Key symptoms not reported: maple syrup odor in urine, lethargy, and neurological problems.

+4. Congenital metabolic disorder (unspecified): Consistent with premature birth, neonatal death, hypertyrosinemia, and hyperphenylalaninemia. Additional information is needed to narrow down the specific disorder.

+5. Severe genetic disorder (unspecified): Consistent with premature birth, neonatal death, and potentially life-threatening condition. Additional information is needed to identify the specific disorder.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Inborn error of metabolism: Consistent with hyperammonemia, increased circulating lactate concentration, hyperglycinemia, hypertyrosinemia, hyperalaninemia, hyperprolinemia, hypervalinemia, abnormal circulating carnitine concentration, hypoglycinemia.

+2. Neurodegenerative disorder: Consistent with delayed speech and language development, intellectual disability, seizure, lethargy, motor delay, generalized hypotonia, tremor, difficulty walking, difficulty climbing stairs, difficulty running, sleep abnormality, severe hearing impairment.

+3. Neurodevelopmental disorder: Consistent with delayed speech and language development, intellectual disability, motor delay, generalized hypotonia.

+4. Primary immunodeficiency: Consistent with leukopenia, recurrent viral infections, pneumonia.

+5. Congenital malformation or chromosomal abnormality: Consistent with multiple system involvement, neonatal death, death in infancy, death in childhood.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Decreased circulating ceruloplasmin concentration, decreased circulating copper concentration, elevated circulating hepatic transaminase concentration. Key symptom not reported: neurological symptoms (e.g., tremors, speech difficulties).

+2. Liver disease (e.g., hepatitis, cirrhosis): Elevated circulating hepatic transaminase concentration, decreased circulating ceruloplasmin concentration, decreased circulating copper concentration. Key symptom not reported: jaundice, abdominal pain, fatigue.

+3. Diabetes mellitus: Polydipsia. Key symptoms not reported: polyuria (frequent urination), polyphagia (increased hunger), weight loss.

+4. Inherited metabolic disorder (e.g., copper metabolism disorder): Decreased circulating ceruloplasmin concentration, decreased circulating copper concentration, elevated circulating hepatic transaminase concentration. Key symptom not reported: specific symptoms may vary depending on the disorder.

+5. Dehydration: Polydipsia. Key symptoms not reported: decreased urine output, dry mouth, dizziness, fatigue.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Pyrimidine metabolism disorder: Consistent with oroticaciduria, neurological symptoms (seizures, lethargy, hypotonia), and potential neonatal death. Key symptoms not reported: developmental delays, failure to thrive.

+2. Urea cycle disorder: Consistent with hyperglutaminemia, neurological symptoms (lethargy, hypotonia), and potential neonatal death. Key symptoms not reported: respiratory alkalosis, ammonia toxicity.

+3. Leukodystrophy: Consistent with neurological symptoms (seizures, lethargy, hypotonia), and potential death in infancy. Key symptoms not reported: vision loss, developmental regression.

+4. Mitochondrial disorder: Consistent with neurological symptoms (seizures, lethargy, hypotonia), and potential neonatal death. Key symptoms not reported: muscle weakness, vision problems, stroke-like episodes.

+5. Severe metabolic disorder: Consistent with the combination of neurological symptoms, vomiting, sleep abnormalities, and potential neonatal death. Specific diagnosis uncertain based on provided information.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Inborn error of metabolism: Consistent with abnormalities in galactoside metabolism, hypergalactosemia, anemia, elevated alkaline phosphatase, and abnormal porphyrin and iron levels. May not fully explain microcephaly, intellectual disability, and developmental delays.

+2. Chromosomal abnormality or genetic syndrome: Microcephaly, intellectual disability, delayed development, and hypotonia are common features. May not account for metabolic abnormalities.

+3. Congenital brain malformation or perinatal brain injury: Could explain microcephaly, developmental delays, hypotonia, and intellectual disability. Metabolic findings may be secondary or unrelated.

+4. Neurodegenerative disorder: Progressive neurological decline, developmental regression, and potential lethality are consistent. Onset and specific symptom profile may vary.

+5. Multisystem congenital disorder: A rare genetic condition affecting multiple organ systems could potentially account for the diverse neurological, developmental, and metabolic manifestations.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, obesity, and potential for early death if untreated. May not fully explain abnormal foot morphology.

+2. Organic acidemia: Consistent with hyperammonemia, obesity, and potential for early death if untreated. May not fully explain abnormal foot morphology.

+3. Prader-Willi syndrome: Consistent with obesity, abnormal growth/development (potentially affecting foot morphology), and increased mortality risk. May not directly cause hyperammonemia.

+4. Congenital liver disease: Consistent with hyperammonemia and potential for early death. May not fully explain obesity and abnormal foot morphology.

+5. Severe congenital anomaly or syndrome: Consistent with the potential for early death and abnormal growth/development (including foot morphology). May not directly cause hyperammonemia or obesity.",Hereditary metabolic disorders
['Canavan disease'],"+1. Leukodystrophy: Abnormal myelination, hyperactivity, feeding difficulties. May not fully explain abnormal amino acid levels or death in infancy.

+2. Organic acidemia: Abnormal circulating aspartate family amino acid concentration, hyperactivity, feeding difficulties. May not directly explain abnormal myelination or death in infancy.

+3. Mitochondrial disorder: Hyperactivity, feeding difficulties, abnormal myelination, abnormal amino acid levels. May not necessarily cause death in infancy.

+4. Peroxisomal disorder: Abnormal myelination, hyperactivity, feeding difficulties, abnormal amino acid levels. May not always result in death in infancy.

+5. Unspecified metabolic disorder: Abnormal circulating aspartate family amino acid concentration, hyperactivity, feeding difficulties, abnormal myelination, death in infancy. Specific diagnosis uncertain without further testing.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Classic symptoms include developmental delays, seizures, and intellectual disability if left untreated.

+2. Congenital malformations: Consistent with abnormality of prenatal development or birth. Specific condition unknown without further details.

+3. Inborn errors of metabolism: Consistent with hyperphenylalaninemia and potential developmental issues. PKU is one example, but other metabolic disorders are possible.

+4. Genetic disorders: Consistent with abnormal prenatal development, neonatal death, and metabolic abnormality. Various genetic conditions affecting multiple body systems could fit this presentation.

+5. Perinatal complications: Consistent with abnormal prenatal development and neonatal death. Complications during pregnancy, childbirth, or the immediate postnatal period could potentially explain these symptoms.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and delayed speech/language development. May not fully explain prenatal/birth abnormalities or early mortality.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential liver dysfunction leading to early mortality. May not explain all developmental delays.

+3. Chromosomal abnormality or genetic syndrome: Could account for prenatal/birth abnormalities, developmental delays, and early mortality. Specific syndrome would depend on genetic testing results.

+4. Severe neurological disorder or brain malformation: Consistent with developmental delays and potential early mortality. May not explain metabolic abnormalities.

+5. Mitochondrial disorder: Could lead to multisystem involvement, including developmental delays, metabolic abnormalities, and potential early mortality. Additional testing may be needed to confirm.",Hereditary metabolic disorders
[],"+1. Congenital heart disease: Consistent with ventricular septal defect, cardiomyopathy, and pulmonic stenosis. May not fully explain other symptoms like nephritis and hypotonia.

+2. Genetic syndrome: Could account for the multi-system involvement (heart, kidneys, muscles) and early mortality. Specific syndrome would depend on genetic testing results.

+3. Metabolic disorder: Certain metabolic disorders can affect multiple organ systems and present with cardiomyopathy, hypotonia, and potentially other symptoms. Further metabolic testing would be needed.

+4. Congenital anomalies syndrome: A syndrome involving multiple congenital anomalies could explain the diverse symptoms across different organ systems. Genetic testing may help identify the specific syndrome.

+5. Neonatal sepsis with multi-organ dysfunction: Severe neonatal infection could potentially lead to multi-organ involvement, including the heart, kidneys, and muscles. However, the symptom of ""death in infancy"" may suggest a more chronic condition.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Hypertyrosinemia, neurological symptoms (irritability, spasticity, hyperreflexia), potential for early death. Key symptom not reported: liver disease.

+2. Phenylketonuria (PKU): Hyperphenylalaninemia, neurological symptoms (irritability, spasticity, hyperreflexia), potential for developmental delays and intellectual disability. Key symptoms not reported: musty odor, eczematous rash, fair skin and hair.

+3. Lesch-Nyhan syndrome: Neurological symptoms (irritability, spasticity, hyperreflexia), recurrent infections, hyperphenylalaninemia. Key symptom not reported: self-mutilating behavior.

+4. Cerebral palsy: Neurological symptoms (spasticity, hyperreflexia, irritability). Key symptoms not reported: metabolic abnormalities, recurrent infections.

+5. Inborn error of metabolism: Combination of neurological symptoms, metabolic abnormalities (hypertyrosinemia, hyperphenylalaninemia), recurrent infections. Specific enzyme deficiency or metabolic pathway affected would need to be identified.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism: Abnormal circulating carnitine concentration, potential developmental abnormalities and early death. Key symptoms not reported: specific metabolic derangements, organ involvement, or clinical presentation depending on the type of IEM.

+2. Congenital malformation: Abnormality of prenatal development or birth, potential cause of neonatal death. Key symptoms not reported: specific details about the type and severity of the malformation.

+3. Genetic disorder: Abnormality of prenatal development or birth, potential cause of neonatal death and metabolic abnormalities. Key symptoms not reported: specific clinical features or family history suggestive of a particular genetic condition.

+4. Perinatal complications: Abnormality of prenatal development or birth, potential cause of neonatal death. Key symptoms not reported: specific details about the complications during pregnancy, labor, or delivery.

+5. Congenital infection: Abnormality of prenatal development or birth, potential cause of neonatal death. Key symptoms not reported: specific signs or symptoms of a congenital infection (e.g., rash, neurological abnormalities, hepatosplenomegaly).",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, developmental delays, and potential early mortality. Key symptom not reported: seizures, musty odor.

+2. Tyrosinemia: Consistent with hypertyrosinemia, developmental delays, and potential early mortality. Key symptoms not reported: liver dysfunction, rickets, neurological crises.

+3. Chromosomal abnormality: Consistent with abnormality of prenatal development, developmental delays, hypotonia, and potential early mortality. Key symptoms not reported: specific dysmorphic features or congenital malformations.

+4. Congenital brain malformation: Consistent with abnormality of prenatal development, developmental delays, hypotonia, and potential early mortality. Key symptoms not reported: specific neurological deficits or seizures.

+5. Mitochondrial disease: Consistent with developmental delays, hypotonia, and potential early mortality. Key symptoms not reported: specific neurological or multi-system involvement, lactic acidosis.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with glutaric aciduria, encephalopathy, seizures, opisthotonus, and potential early death. May not exhibit all symptoms, such as decreased plasma free carnitine.

+2. Methylmalonic acidemia: Consistent with encephalopathy, seizures, elevated urinary carboxylic acid, and potential early death. May not exhibit glutaric aciduria or opisthotonus.

+3. Propionic acidemia: Consistent with encephalopathy, seizures, elevated urinary carboxylic acid, and potential early death. May not exhibit glutaric aciduria or opisthotonus.

+4. Mitochondrial encephalomyopathy: Consistent with encephalopathy, seizures, and potential early death. May not exhibit metabolic abnormalities like glutaric aciduria or elevated urinary carboxylic acid.

+5. Leigh syndrome: Consistent with encephalopathy, seizures, and potential early death. May not exhibit metabolic abnormalities like glutaric aciduria or elevated urinary carboxylic acid.",Hereditary metabolic disorders
[],"+1. Mitochondrial disorder: Consistent with neurological symptoms (seizures, hypotonia, spasticity), metabolic acidosis, multi-system involvement. Key symptoms not reported: muscle weakness, vision loss, cardiomyopathy.

+2. Leukodystrophy: Consistent with neurological symptoms (intellectual disability, seizures, spasticity), fair/white hair. Key symptoms not reported: progressive neurological decline, vision loss.

+3. Inborn error of metabolism: Consistent with metabolic acidosis, hyperkalemia, hypocalcemia, multi-system involvement. Key symptoms not reported: specific metabolic abnormalities based on the type of disorder.

+4. Neuromuscular disorder: Consistent with neurological symptoms (hypotonia, spasticity, motor delay), respiratory symptoms (cyanosis, dyspnea, stridor). Key symptoms not reported: muscle weakness, respiratory failure.

+5. Congenital malformation syndrome: Consistent with multi-system involvement, intellectual disability, hearing impairment. Key symptoms not reported: specific malformations or dysmorphic features.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Ataxia-telangiectasia (A-T): Consistent with strabismus, intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, cirrhosis, hepatic fibrosis, thromboembolism, and reduced antithrombin III activity. Key symptom not reported: telangiectasias.

+2. Niemann-Pick disease type C: Consistent with intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, cirrhosis, hepatic fibrosis, and lipodystrophy. Key symptoms not reported: enlarged spleen, lung involvement.

+3. Zellweger spectrum disorders: Consistent with intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, cirrhosis, hepatic fibrosis, and death in infancy/childhood. Key symptoms not reported: hearing loss, vision problems.

+4. Leigh syndrome (mitochondrial disorder): Consistent with intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, and cirrhosis. Key symptoms not reported: seizures, stroke-like episodes.

+5. MELAS (mitochondrial disorder): Consistent with intellectual disability, ataxia, motor delay, cerebellar atrophy, generalized hypotonia, and cirrhosis. Key symptoms not reported: seizures, stroke-like episodes.",Hereditary metabolic disorders
['Canavan disease'],"+1. Maple syrup urine disease: Consistent with abnormal circulating aspartate family amino acid concentration, seizures, hypotonia, and feeding difficulties. Classic symptom of maple syrup odor in urine or sweat may not be reported.

+2. Phenylketonuria: Consistent with abnormal circulating aspartate family amino acid concentration, seizures, and developmental delays (irritability, feeding difficulties). Hyperpigmentation and musty odor may not be reported.

+3. Infantile spasms: Consistent with seizures, hypotonia, and developmental delays (irritability, feeding difficulties). Hypsarrhythmia on EEG and clustering of spasms may not be reported.

+4. Hypoxic-ischemic encephalopathy: Consistent with seizures, hypotonia, hyperreflexia, and feeding difficulties. History of perinatal asphyxia or complications may not be provided.

+5. Neuromuscular disorder (e.g., spinal muscular atrophy): Consistent with hypotonia, hyperreflexia, and feeding difficulties. Specific muscle weakness patterns or respiratory involvement may not be reported.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Consistent with hypertyrosinemia, hyperphenylalaninemia, and gastrointestinal inflammation. May not fully explain prenatal abnormalities or infant mortality.

+2. Chromosomal abnormality or genetic syndrome: Could account for the range of symptoms, including prenatal developmental issues, amino acid imbalances, gastrointestinal problems, and potential lethality.

+3. Severe congenital malformation or birth defect: Consistent with abnormality of prenatal development, gastrointestinal inflammation, and potential for infant mortality. May not explain the specific amino acid abnormalities.

+4. Inherited metabolic disorder involving the liver or gastrointestinal system: Could explain the combination of elevated amino acid levels, gastrointestinal inflammation, and potential complications leading to infant death.

+5. Congenital infection or intrauterine exposure: Prenatal infections or exposures could potentially cause developmental abnormalities, gastrointestinal issues, and other systemic complications, although the amino acid abnormalities are less typical.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Leukodystrophy: Consistent with ataxia, coma, reduced tendon reflexes, cerebral edema, abnormal cerebral white matter morphology, and potential death in childhood/adolescence. Key symptom not reported: progressive cognitive and motor decline.

+2. Maple syrup urine disease: Consistent with ataxia, coma, reduced tendon reflexes, metabolic acidosis, hyperleucinemia, and potential death in childhood/adolescence. Key symptom not reported: maple syrup odor in urine and sweat.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections and potential death in childhood/adolescence. Key symptoms not reported: chronic diarrhea, failure to thrive, and opportunistic infections.

+4. Mitochondrial disease: Consistent with ataxia, coma, reduced tendon reflexes, metabolic acidosis, and potential death in childhood/adolescence. Key symptoms not reported: muscle weakness, vision or hearing problems, and developmental delays.

+5. Adrenoleukodystrophy: Consistent with ataxia, coma, reduced tendon reflexes, cerebral edema, abnormal cerebral white matter morphology, and potential death in childhood/adolescence. Key symptom not reported: progressive vision loss or blindness.",Hereditary metabolic disorders
['Acute intermittent porphyria'],"+1. Acute porphyria: Abdominal pain and elevated urinary delta-aminolevulinic acid are consistent with an acute porphyria attack. Childhood death could be due to severe complications.

+2. Lead poisoning: Elevated urinary delta-aminolevulinic acid can be seen in lead poisoning, but abdominal pain and childhood death are less typical.

+3. Hereditary tyrosinemia type 1: Childhood death is consistent with this rare metabolic disorder, but abdominal pain and elevated urinary delta-aminolevulinic acid are not typical presenting symptoms.

+4. Acute intermittent porphyria: A specific type of acute porphyria characterized by abdominal pain, neurological symptoms, and elevated porphyrin precursors like delta-aminolevulinic acid. Childhood death could occur due to severe complications.

+5. Variegate porphyria: Another type of acute porphyria that can present with abdominal pain, neurological symptoms, and elevated porphyrin precursors. Childhood death is possible with severe complications.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with methylmalonic aciduria, metabolic acidosis, seizures, and potential for death in infancy if untreated.

+2. Propionic acidemia: Consistent with methylmalonic aciduria, metabolic acidosis, seizures, and potential for death in infancy if untreated.

+3. Organic acidemias: Consistent with metabolic acidosis, methylmalonic aciduria, seizures, and potential for death in infancy if untreated.

+4. Mitochondrial disorders: Consistent with metabolic acidosis, seizures, and potential for death in infancy. However, methylmalonic aciduria is not a typical feature.

+5. Neonatal epilepsy syndromes: Consistent with seizures and potential for neonatal death. However, metabolic acidosis and methylmalonic aciduria are not typical features.",Hereditary metabolic disorders
['Alkaptonuria'],"+1. Metabolic disorder: Consistent with seizures, lethargy, hypotonia, growth delay, drowsiness, sleep abnormality, and dark urine. Key symptoms not reported may include vomiting, acidosis, or specific metabolic abnormalities on testing.

+2. Leukodystrophy: Consistent with seizures, lethargy, hypotonia, growth delay, drowsiness, and sleep abnormality. Key symptoms not reported may include vision problems, spasticity, or specific patterns on brain imaging.

+3. Mitochondrial disorder: Consistent with seizures, lethargy, hypotonia, growth delay, drowsiness, sleep abnormality, and potentially dark urine. Key symptoms not reported may include muscle weakness, vision or hearing problems, or specific metabolic abnormalities.

+4. Genetic epilepsy syndrome: Consistent with seizures, lethargy, hypotonia, and potentially drowsiness and sleep abnormality. Key symptoms not reported may include specific seizure types, developmental regression, or other neurological findings.

+5. Structural brain abnormality: Consistent with seizures, lethargy, hypotonia, growth delay, drowsiness, and sleep abnormality. Key symptoms not reported may include specific neurological deficits or patterns on brain imaging.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple Syrup Urine Disease (MSUD): Consistent with seizures, aminoaciduria, and abnormal circulating levels of leucine, isoleucine, and valine.

+2. Urea Cycle Disorder: Consistent with seizures, aminoaciduria, and neonatal/infant death. However, abnormal branched-chain amino acid levels are not typical.

+3. Organic Acidemia: Consistent with seizures and potential neonatal/infant death. However, aminoaciduria and abnormal branched-chain amino acid levels are not typical.

+4. Mitochondrial Disorder: Consistent with seizures and potential neonatal/infant death. However, aminoaciduria and abnormal branched-chain amino acid levels are not typical.

+5. Aminoacidopathy (other than MSUD): Consistent with aminoaciduria and potentially seizures. However, the specific abnormal amino acid levels reported are not typical.",Hereditary metabolic disorders
['Very long chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Consistent with hypoglycemia, cardiomegaly, hepatomegaly, dicarboxylic aciduria, and abnormal carnitine levels. May not fully explain recurrent viral infections.

+2. Mitochondrial disorder: Consistent with multi-organ involvement (cardiomegaly, hepatomegaly), lactic acidosis, and potential energy deficiency. May not directly cause recurrent viral infections.

+3. Primary immunodeficiency disorder: Consistent with recurrent viral infections. May not fully account for metabolic abnormalities.

+4. Organic acidemia: Consistent with dicarboxylic aciduria, hypoglycemia, and potential metabolic decompensation. May not directly cause cardiomegaly or hepatomegaly.

+5. Congenital disorder of glycosylation: Consistent with multi-organ involvement and potential metabolic derangements. May not directly cause recurrent viral infections or dicarboxylic aciduria.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Glutaric acidemia type I (GA1): Consistent with glutaric aciduria, metabolic acidosis, hypoglycemia, progressive neurologic deterioration, and potential death in infancy/childhood. Key symptoms not reported: macrocephaly, dystonia.

+2. Methylglutaconic aciduria: Consistent with 3-methylglutaric aciduria, metabolic acidosis, lethargy, and potential death in infancy/childhood. Specific subtype and additional symptoms would depend on the underlying cause.

+3. Mitochondrial disorder: Consistent with metabolic acidosis, hypoglycemia, lethargy, seizures, progressive neurologic deterioration, and potential death in infancy/childhood. Specific symptoms may vary based on the affected mitochondrial function.

+4. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration, seizures, lethargy, progressive neurologic deterioration, and potential death in infancy/childhood. May also present with respiratory issues and developmental delays.

+5. Inborn error of metabolism (unspecified): Consistent with the combination of metabolic, neurologic, and systemic symptoms, including metabolic acidosis, hypoglycemia, seizures, lethargy, and potential death in infancy/childhood. Specific diagnosis would depend on further testing.",Hereditary metabolic disorders
['MODY'],"+1. Diabetes mellitus: Consistent with hypoglycemia and glycosuria. May not explain abnormal porphyrin levels.

+2. Porphyria: Consistent with abnormal porphyrin levels. Hypoglycemia and glycosuria are less common symptoms.

+3. Liver disease: Consistent with all three symptoms (hypoglycemia, glycosuria, and abnormal porphyrin levels).

+4. Kidney disease: Consistent with glycosuria. May not fully explain hypoglycemia and abnormal porphyrin levels.

+5. Endocrine disorder: Consistent with hypoglycemia and potentially abnormal porphyrin levels. Glycosuria may or may not be present, depending on the specific condition.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential developmental abnormalities or neonatal death. Key symptom not reported: intellectual disability if left untreated.

+2. Congenital malformations: Consistent with ""Abnormality of prenatal development or birth."" Additional details about the specific abnormality would be needed for a more precise diagnosis.

+3. Inborn errors of metabolism: Consistent with hyperphenylalaninemia and potential developmental issues or neonatal death. Additional metabolic testing and genetic analysis may be required for a specific diagnosis.

+4. Genetic syndromes: Consistent with developmental abnormalities and potential neonatal complications. More information about the specific symptoms and clinical presentation would be needed to consider specific syndromes.

+5. Perinatal complications: Consistent with neonatal death and abnormalities during prenatal development or birth. Additional details about the pregnancy, delivery, and neonatal course would be helpful in evaluating this possibility.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Leukodystrophy: Consistent with hydrocephalus, macrocephaly, seizures, lethargy, dystonia, hyperreflexia, cerebral atrophy, and death in infancy/childhood. May not explain fever, vomiting, or increased CSF protein.

+2. Lysosomal storage disorder: Consistent with hydrocephalus, macrocephaly, seizures, lethargy, anemia, and neurological symptoms. May not explain fever, vomiting, or increased CSF protein.

+3. Glutaric aciduria type 1: Consistent with macrocephaly, seizures, lethargy, and neurological symptoms. May not explain fever, vomiting, or increased CSF protein.

+4. Viral encephalitis/meningitis: Consistent with fever, vomiting, increased CSF protein, seizures, and neurological symptoms. May not explain macrocephaly or death in infancy/childhood.

+5. Neurodegenerative disorder (e.g., Leigh syndrome, mitochondrial disorder): Consistent with seizures, lethargy, dystonia, hyperreflexia, cerebral atrophy, and progressive deterioration. May not explain macrocephaly, fever, vomiting, or increased CSF protein.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, potential for developmental abnormalities and intellectual disability if untreated. Key symptom not reported: fair skin, blue eyes, musty odor.

+2. Tyrosinemia type I: Hypertyrosinemia, potential for liver disease, neurological problems, and early death if untreated. Key symptom not reported: cabbage-like odor.

+3. Congenital malformation syndrome: Abnormality of prenatal development, potential for multi-organ involvement and early mortality. Additional details on specific malformations would help narrow the diagnosis.

+4. Severe perinatal asphyxia: Could explain neonatal death and potential for abnormal prenatal development due to lack of oxygen. Additional details on delivery and neonatal course would be helpful.

+5. Prematurity complications: Preterm birth could lead to abnormal prenatal development and increased risk of neonatal/infant mortality. Gestational age and details on neonatal course would provide more clarity.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Patients may also experience developmental delays, seizures, and other neurological symptoms if left untreated.

+2. Tyrosinemia: Consistent with hypertyrosinemia. Patients may also experience liver dysfunction, kidney problems, and neurological issues if left untreated.

+3. Acute liver failure: Consistent with elevated amino acid levels and potential for early death. Patients may also experience jaundice, nausea, confusion, and other symptoms related to liver dysfunction.

+4. Preeclampsia: Consistent with the reported symptom. However, it does not directly explain the elevated amino acid levels. Additional information about the patient's pregnancy history would be helpful.

+5. Metabolic disorder (unspecified): The combination of elevated amino acid levels and early death suggests a possible underlying metabolic disorder, but more information is needed for a specific diagnosis.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, potential for developmental abnormalities and neurological complications if untreated. Key symptom not reported: intellectual disability.

+2. Tyrosinemia: Hypertyrosinemia, elevated urinary carboxylic acid, potential for liver disease, neurological issues, and early death if untreated. Key symptom not reported: liver dysfunction.

+3. Maple syrup urine disease (MSUD): Elevated branched-chain amino acids, potential for neonatal seizures, coma, and early death if untreated. Key symptom not reported: maple syrup odor in urine.

+4. Congenital malformation or chromosomal abnormality: Abnormality of prenatal development or birth, potential for multi-organ dysfunction and early mortality.

+5. Mitochondrial disorder: Multi-system involvement, potential for developmental delays, metabolic abnormalities, and early mortality. Key symptom not reported: specific neurological or muscular manifestations.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. May also present with developmental delays, seizures, and other neurological symptoms if untreated.

+2. Tyrosinemia: Consistent with hypertyrosinemia. Can lead to liver disease, kidney dysfunction, and neurological complications if untreated.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development and potential for early mortality. Examples include trisomies, neural tube defects, and multiple congenital anomaly syndromes.

+4. Severe perinatal asphyxia: Consistent with neonatal death or developmental abnormalities due to lack of oxygen during the perinatal period.

+5. Prematurity complications: Consistent with neonatal death or developmental abnormalities in premature infants due to immature organ systems and potential complications.",Hereditary metabolic disorders
['Hereditary orotic aciduria'],"+1. Inborn error of metabolism: Consistent with metabolic abnormalities, multi-system involvement, and early onset. Key symptoms not reported: specific metabolic derangements or dysmorphic features associated with certain disorders.

+2. Immunodeficiency: Consistent with recurrent infections, skin rash, and hepatosplenomegaly. Key symptoms not reported: specific laboratory abnormalities or clinical features of particular immunodeficiencies.

+3. Sepsis: Consistent with fever, lethargy, and multi-organ involvement. Key symptoms not reported: specific source of infection or positive blood cultures.

+4. Malignancy: Consistent with hepatosplenomegaly, lethargy, and metabolic abnormalities. Key symptoms not reported: specific tumor markers or imaging findings.

+5. Autoimmune or inflammatory disorder: Consistent with multi-system involvement and skin manifestations. Key symptoms not reported: specific autoantibodies or clinical features of particular disorders.",Hereditary metabolic disorders
['Holocarboxylase synthetase deficiency'],"+1. Organic acidemia: Consistent with metabolic acidosis, hyperammonemia, aminoaciduria, abnormal circulating monocarboxylic acid and carboxylic acid levels. Key symptoms like vomiting and lethargy are not mentioned.

+2. Respiratory distress syndrome: Consistent with cyanosis, tachypnea, and hypotonia. Does not explain metabolic abnormalities.

+3. Congenital heart defect: Consistent with cyanosis and tachypnea. Does not explain metabolic abnormalities.

+4. Sepsis: Consistent with tachypnea and metabolic acidosis. Fever and poor feeding, which are common in sepsis, are not mentioned.

+5. Inborn error of glycine metabolism: Consistent with abnormal circulating glycine concentration. Does not explain other metabolic abnormalities.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, lethargy, vomiting, and potential for early death. Key symptoms like protein aversion and episodic nature are not reported.

+2. Leukodystrophy: Consistent with ataxia, lethargy, drowsiness, sleep abnormality, and potential for early death. Metabolic abnormalities like hyperammonemia and oroticaciduria are not typical.

+3. Mitochondrial disorder: Consistent with ataxia, lethargy, vomiting, drowsiness, and sleep abnormality. Hyperammonemia and oroticaciduria are less common.

+4. Organic acidemia: Consistent with hyperammonemia, lethargy, vomiting, and neurological symptoms. Oroticaciduria is less common.

+5. Peroxisomal disorder: Consistent with ataxia, lethargy, vomiting, and potential for early death. Hyperammonemia and oroticaciduria are less common.",Hereditary metabolic disorders
[],"+1. Ethylmalonic encephalopathy (EE) or Ethylmalonic aciduria: Consistent with ethylmalonic aciduria, abnormal carnitine levels, decreased 3-hydroxyacyl-CoA dehydrogenase activity, vomiting, and early death.

+2. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD): Consistent with abnormal carnitine levels, decreased 3-hydroxyacyl-CoA dehydrogenase activity, and vomiting. Does not typically cause ethylmalonic aciduria.

+3. Carnitine deficiency: Consistent with abnormal carnitine levels and vomiting. Does not explain ethylmalonic aciduria or decreased enzyme activity.

+4. Methylmalonic acidemia: Consistent with vomiting and potential organic aciduria. Does not typically cause ethylmalonic aciduria specifically.

+5. Other organic acidemias: Consistent with vomiting and potential organic aciduria. Ethylmalonic aciduria is not a typical symptom.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with dysmorphic facial features, developmental delays, musculoskeletal abnormalities, feeding difficulties, hypocholesterolemia, elevated 8-dehydrocholesterol, and elevated circulating 7-dehydrocholesterol concentration.

+2. Trisomy 18 (Edwards syndrome): Consistent with dysmorphic facial features, developmental delays, musculoskeletal abnormalities, and feeding difficulties. Does not typically involve abnormal cholesterol levels.

+3. Prader-Willi syndrome: Consistent with intellectual disability, hypotonia, and feeding difficulties. Does not typically involve dysmorphic facial features or abnormal cholesterol levels.

+4. Congenital disorders of glycosylation (CDG): Consistent with developmental delays, hypotonia, and feeding difficulties. Does not typically involve dysmorphic facial features or abnormal cholesterol levels.

+5. Neonatal adrenoleukodystrophy: Consistent with developmental delays, hypotonia, and feeding difficulties. Does not typically involve dysmorphic facial features or abnormal cholesterol levels.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. L-2-hydroxyglutaric aciduria: Consistent with intellectual disability, ataxia, tremor, cerebral atrophy, abnormal basal ganglia morphology, and L-2-hydroxyglutaric aciduria. Does not typically cause death in infancy or childhood unless severe.

+2. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with intellectual disability, ataxia, cerebral atrophy, abnormal basal ganglia morphology, death in infancy, and death in childhood. Tremor and L-2-hydroxyglutaric aciduria are not typical features.

+3. Neuronal ceroid lipofuscinosis (NCL): Consistent with intellectual disability, ataxia, cerebral atrophy, death in infancy, and death in childhood. Tremor and L-2-hydroxyglutaric aciduria are not common symptoms.

+4. GM1 gangliosidosis: Consistent with intellectual disability, ataxia, cerebral atrophy, abnormal basal ganglia morphology, death in infancy, and death in childhood. Tremor and L-2-hydroxyglutaric aciduria are not typical features.

+5. Congenital brain malformation or chromosomal abnormality: Consistent with intellectual disability, ataxia, cerebral atrophy, abnormal basal ganglia morphology, death in infancy, and death in childhood. Tremor and L-2-hydroxyglutaric aciduria are not common symptoms.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Leigh syndrome: Consistent with seizures, generalized hypotonia, metabolic acidosis, opisthotonus, and death in infancy/childhood. Key symptoms not reported: developmental regression, respiratory difficulties.

+2. Glutaric acidemia type 1: Consistent with seizures, generalized hypotonia, metabolic acidosis, dicarboxylic aciduria, 3-methylglutaconic aciduria, and elevated urinary carboxylic acid. Key symptom not reported: macrocephaly (enlarged head).

+3. Methylmalonic acidemia: Consistent with seizures, generalized hypotonia, metabolic acidosis, and elevated urinary carboxylic acid. Key symptoms not reported: developmental delay, recurrent vomiting, and failure to thrive.

+4. Pyridoxine-dependent epilepsy: Consistent with seizures, irritability, and opisthotonus. Key symptoms not reported: pyridoxine (vitamin B6) responsiveness, anemia, and developmental delay.

+5. Mitochondrial encephalomyopathy: Consistent with seizures, generalized hypotonia, metabolic acidosis, and death in infancy/childhood. Key symptoms not reported: lactic acidosis, developmental regression, and multisystem involvement.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. Organic aciduria: Consistent with L-2-hydroxyglutaric aciduria, seizures, and potential early lethality. May not fully explain the skin rash or elevated C-reactive protein.

+2. Leukodystrophy: Consistent with seizures, neurological symptoms, and potential early lethality. May not fully explain the metabolic abnormalities or skin rash.

+3. Vasculitis: Consistent with skin rash, fever, and elevated C-reactive protein. May not explain the metabolic abnormalities, seizures, or potential early lethality.

+4. Mitochondrial disorder: Consistent with seizures, metabolic abnormalities, and potential early lethality. May not fully explain the skin rash or elevated C-reactive protein.

+5. Peroxisomal disorder: Consistent with neurological symptoms, metabolic abnormalities, and potential early lethality. May not fully explain the skin rash or elevated C-reactive protein.",Hereditary metabolic disorders
['X-linked hypophosphatemia'],"+1. Hypophosphatemic rickets: Consistent with hypophosphatemia, abnormal limb bone morphology, nephritis, and elevated alkaline phosphatase. Key symptoms not reported: short stature, muscle weakness.

+2. Osteogenesis imperfecta (OI): Consistent with abnormal limb bone morphology and potential for early death. Key symptoms not reported: bone fractures, blue sclera, hearing loss.

+3. Vitamin D deficiency rickets: Consistent with hypophosphatemia, abnormal limb bone morphology, and potential for nephritis. Key symptoms not reported: muscle weakness, bone pain.

+4. Chronic kidney disease (CKD): Consistent with nephritis and potential for abnormal hormone levels. Key symptoms not reported: fatigue, edema, hypertension.

+5. Metabolic bone disorder (e.g., hypophosphatasia, X-linked hypophosphatemia): Consistent with hypophosphatemia, abnormal limb bone morphology, and elevated alkaline phosphatase. Key symptoms not reported: muscle weakness, bone pain.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Inborn error of metabolism: Delayed speech and language development, hyperammonemia, hyperglycinemia, hyperglycinuria, elevated circulating alkaline phosphatase concentration, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, abnormal circulating carnitine concentration, abnormal circulating serine concentration, elevated urinary carboxylic acid. Key symptoms not reported: specific metabolic abnormalities may vary depending on the disorder.

+2. Immunodeficiency disorder: Skin rash, leukopenia. Key symptoms not reported: recurrent infections, failure to thrive, chronic diarrhea.

+3. Peroxisomal disorder: Delayed speech and language development, skin rash, leukopenia, elevated circulating alkaline phosphatase concentration, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, abnormal circulating carnitine concentration, abnormal circulating serine concentration. Key symptoms not reported: developmental regression, vision and hearing impairment, seizures.

+4. Mitochondrial disorder: Delayed speech and language development, skin rash, leukopenia, elevated circulating alkaline phosphatase concentration, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration, abnormal circulating carnitine concentration, abnormal circulating serine concentration. Key symptoms not reported: muscle weakness, seizures, vision and hearing impairment, cardiomyopathy.

+5. Hematological malignancy: Leukopenia. Key symptoms not reported: fever, night sweats, weight loss, fatigue, bone pain, lymphadenopathy.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Methylmalonic acidemia: Consistent with methylmalonic aciduria, hyperhomocystinemia, developmental delays, hypotonia, gastrointestinal inflammation, and potential early death. Abnormal cerebral white matter morphology is also seen in severe cases.

+2. Propionic acidemia: Consistent with methylmalonic aciduria, hyperhomocystinemia, developmental delays, hypotonia, gastrointestinal inflammation, decreased plasma free carnitine, and potential early death. Abnormal cerebral white matter morphology can also occur.

+3. Carnitine deficiency: Consistent with decreased plasma free carnitine, developmental delays, hypotonia, and gastrointestinal inflammation. Does not explain methylmalonic aciduria, hyperhomocystinemia, or cerebral white matter abnormalities.

+4. Leukodystrophy: Consistent with abnormal cerebral white matter morphology, developmental delays, and hypotonia. Does not typically present with methylmalonic aciduria, hyperhomocystinemia, or gastrointestinal inflammation.

+5. Mitochondrial disorder: Consistent with developmental delays, hypotonia, gastrointestinal inflammation, and potential early death. Methylmalonic aciduria and hyperhomocystinemia are not common features.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid and potential for neonatal/infant death if untreated. Key symptoms may include metabolic acidosis, lethargy, vomiting, and developmental delays.

+2. Fatty acid oxidation disorder: Consistent with neonatal/infant death and potential metabolic derangements. May also present with hypoglycemia, liver dysfunction, and cardiomyopathy.

+3. Mitochondrial disorder: Consistent with multi-organ dysfunction, potential for neonatal/infant death, and elevated organic acid levels. Other symptoms may include neurological abnormalities, muscle weakness, and failure to thrive.

+4. Congenital disorder of glycosylation: A group of metabolic disorders that can lead to multi-system involvement, including neurological impairment and potential for neonatal/infant death. May also present with developmental delays and dysmorphic features.

+5. Peroxisomal disorder: Disorders affecting peroxisome function can result in elevated organic acid levels, neurological symptoms, and potentially neonatal/infant death. Other symptoms may include hepatic dysfunction, skeletal abnormalities, and visual impairment.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Urea cycle disorder: Hyperammonemia, lethargy, drowsiness, sleep abnormality, feeding difficulties, and potential for neonatal death are consistent with a urea cycle defect. Key symptoms not reported: vomiting, seizures, coma.

+2. Leukodystrophy: Spasticity, generalized hypotonia, hyperreflexia, lethargy, drowsiness, sleep abnormality, feeding difficulties, and potential for death in infancy are consistent with a leukodystrophy. Key symptoms not reported: vision problems, seizures, cognitive decline.

+3. Mitochondrial disorder: Lethargy, spasticity, generalized hypotonia, hyperreflexia, drowsiness, sleep abnormality, feeding difficulties, and potential for death in infancy are consistent with a mitochondrial disorder. Key symptoms not reported: seizures, stroke-like episodes, muscle weakness.

+4. Spinal muscular atrophy (SMA): Generalized hypotonia, hyperreflexia, and feeding difficulties are consistent with SMA. Key symptoms not reported: progressive muscle weakness, respiratory difficulties.

+5. Glycogen storage disease: Generalized hypotonia, lethargy, and feeding difficulties are consistent with a glycogen storage disorder. Key symptoms not reported: hepatomegaly, hypoglycemia, muscle weakness.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with decreased methylmalonyl-CoA mutase activity, metabolic acidosis, and potential for death in infancy/childhood. Key symptom not reported: Developmental delays, seizures, or other neurological issues often seen in MMA.

+2. Propionic acidemia: Consistent with metabolic acidosis and potential for death in infancy/childhood. Does not explain the specific enzyme deficiency reported.

+3. Isovaleric acidemia: Consistent with metabolic acidosis and potential for death in infancy/childhood. Does not explain the specific enzyme deficiency reported.

+4. Mitochondrial disorder: Consistent with metabolic acidosis and potential for death in infancy/childhood. Does not explain the specific enzyme deficiency reported.

+5. Other inborn error of metabolism: Consistent with metabolic acidosis and potential for death in infancy/childhood. Does not explain the specific enzyme deficiency reported.",Hereditary metabolic disorders
[],"+1. Porphyria: Abnormal circulating porphyrin concentration, potential neurological symptoms (hyperactivity, spasticity), hemolytic anemia, and metabolic acidosis are consistent with acute porphyrias.

+2. Mitochondrial disorder: Metabolic acidosis, neurological symptoms (hyperactivity, spasticity, neonatal death), recurrent viral infections (potential immunodeficiency), and increased lactate dehydrogenase are seen in mitochondrial disorders. Hemolytic anemia is not a typical feature.

+3. Lesch-Nyhan syndrome: Hyperactivity, spasticity, and neonatal/infant death fit this disorder, but hemolytic anemia, metabolic acidosis, and increased bilirubin are not common features.

+4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Hemolytic anemia is a key symptom, but the neurological symptoms, metabolic acidosis, and increased bilirubin are not typically seen in this condition.

+5. Congenital immunodeficiency: Recurrent viral infections suggest an immunodeficiency, but the other symptoms (neurological, hematological, and metabolic) are not commonly associated with primary immunodeficiencies.",Hereditary metabolic disorders
['Neonatal intrahepatic cholestasis due to citrin deficiency'],"+1. Citrullinemia: Consistent with hyperammonemia, elevated plasma citrulline, respiratory distress, and neonatal onset. Key symptom not reported: neurological symptoms (seizures, lethargy).

+2. Argininosuccinic aciduria: Consistent with hyperammonemia, respiratory distress, and neonatal onset. Key symptom not reported: trichorrhexis nodosa (brittle, sparse hair).

+3. Respiratory distress syndrome (RDS): Consistent with premature birth, respiratory distress, and hypoxemia. Does not fully explain metabolic abnormalities.

+4. Organic acidemia: Consistent with hyperammonemia, respiratory distress, and metabolic acidosis. Additional tests needed to identify specific disorder.

+5. Fatty acid oxidation disorder: Consistent with hypoglycemia, metabolic acidosis, and neonatal onset. Additional tests needed for confirmation.",Hereditary metabolic disorders
[],"+1. Methylmalonic acidemia: Consistent with methylmalonic acidemia, methylmalonic aciduria, increased circulating methylmalonic acid, and metabolic disturbances. Key symptoms not reported: macrocytic anemia, developmental delay.

+2. Mitochondrial disorder: Consistent with autistic behavior, intellectual disability, seizures, hypotonia, lactic acidosis, and multi-system involvement. Key symptoms not reported: muscle weakness, exercise intolerance, vision/hearing problems.

+3. Leukodystrophy: Consistent with autistic behavior, intellectual disability, seizures, hypotonia, and neurological deterioration. Key symptoms not reported: progressive demyelination on brain imaging, spasticity, optic atrophy.

+4. Organic acidemia: Consistent with metabolic acidosis, hyperammonemia, hyperglycinemia, and multi-system involvement. Key symptoms not reported: specific metabolic abnormalities based on the type of organic acidemia.

+5. Lysosomal storage disorder: Consistent with intellectual disability, seizures, organomegaly (pancreatitis), and multi-system involvement. Key symptoms not reported: coarse facial features, skeletal abnormalities, cherry-red spot on the macula.",Hereditary metabolic disorders
['Dihydropteridine reductase deficiency'],"+1. Inborn Error of Metabolism: Consistent with hypertyrosinemia, hyperphenylalaninemia, intellectual disability, seizures, and other neurological symptoms. May not explain microcephaly or cerebral atrophy.

+2. Leukodystrophy: Consistent with abnormal cerebral white matter morphology, motor delay, intellectual disability, and other neurological manifestations. May not explain amino acid abnormalities.

+3. Congenital Brain Malformation: Consistent with microcephaly, intellectual disability, motor delay, seizures, and abnormality of prenatal development or birth. May not explain amino acid abnormalities or white matter changes.

+4. Neurodegenerative Disorder: Consistent with cerebral atrophy, intellectual disability, motor delay, and seizures. Early onset and severity may not fit typical presentation.

+5. Severe Congenital Disorder: Consistent with the broad range of symptoms, including microcephaly, neurological deficits, metabolic abnormalities, and potential lethality (neonatal/childhood death). Specific diagnosis uncertain without further testing.",Hereditary metabolic disorders
[],"+1. Mitochondrial disorder: Consistent with cytochrome C oxidase-negative muscle fibers, ethylmalonic aciduria, glycosuria, feeding difficulties, and gastrointestinal abnormalities. Key symptoms like neurological manifestations, lactic acidosis, and developmental delays are not mentioned.

+2. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration, ethylmalonic aciduria, and death in infancy. Neurological symptoms like seizures, lethargy, and developmental delays are not mentioned.

+3. Methylmalonic acidemia: Consistent with ethylmalonic aciduria, glycosuria, and feeding difficulties. Symptoms like metabolic acidosis, lethargy, and developmental delays are not mentioned.

+4. Severe combined immunodeficiency (SCID): Consistent with skin rash and gastrointestinal abnormalities. Key symptoms like recurrent infections, failure to thrive, and lymphopenia are not mentioned.

+5. Epidermolysis bullosa: Consistent with skin rash (erythematous plaque, macule, papule). Other symptoms like blistering, erosions, and scarring are not mentioned.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Urea cycle disorder (UCD): Consistent with hyperammonemia, cyanosis, seizures, cerebral edema, oroticaciduria, low plasma citrulline, hypoargininemia, and neonatal death. Key symptom not reported: vomiting.

+2. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with hyperammonemia, cyanosis, seizures, cerebral edema, oroticaciduria, low plasma citrulline, and neonatal death. Key symptom not reported: protein avoidance.

+3. Argininosuccinic aciduria (ASA): Consistent with hyperammonemia, cyanosis, seizures, cerebral edema, hypoargininemia, and neonatal death. Key symptom not reported: trichorrhexis nodosa (brittle hair).

+4. Mitochondrial disorder: Consistent with seizures, cerebral edema, and neonatal death. Key symptoms not reported: lactic acidosis, muscle weakness, and developmental delays.

+5. Organic acidemia: Consistent with seizures, cerebral edema, and neonatal death. Key symptoms not reported: metabolic acidosis, vomiting, and failure to thrive.",Hereditary metabolic disorders
['Canavan disease'],"+1. Urea cycle disorder: Consistent with hyperammonemia, aminoaciduria, neonatal/infant death. Key symptom not reported: vomiting, lethargy.

+2. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration, seizures, neonatal/infant death. Key symptom not reported: developmental delay, hypotonia.

+3. Phenylketonuria: Consistent with aminoaciduria, abnormal circulating amino acid concentration. Key symptoms not reported: developmental delay, musty odor, fair skin and hair.

+4. Maple syrup urine disease: Consistent with aminoaciduria, abnormal circulating amino acid concentration. Key symptoms not reported: maple syrup odor, lethargy, poor feeding.

+5. Autoimmune or inflammatory condition: Consistent with skin rash (erythematous lesions). Key symptoms not reported: fever, joint pain, fatigue.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, seizures, respiratory insufficiency, feeding difficulties, and neonatal death. Lack of reported maple syrup odor in urine.

+2. Phenylketonuria (PKU): Consistent with seizures, developmental delay, feeding difficulties, and neonatal death. Elevated phenylalanine levels not reported.

+3. Homocystinuria: Consistent with seizures, developmental delay, respiratory insufficiency, and neonatal death. Elevated homocysteine levels not reported.

+4. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with seizures, developmental delay, respiratory insufficiency, feeding difficulties, and neonatal death. Specific organic acid elevations not reported.

+5. Congenital infection (e.g., TORCH infections, meningitis): Consistent with seizures, respiratory insufficiency, opisthotonus, sepsis, and neonatal death. Metabolic abnormalities less likely with this diagnosis.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorders (FAODs): Consistent with abnormal carnitine concentration, decreased 3-hydroxyacyl-CoA dehydrogenase level, and potential for neonatal/infant/childhood death.

+2. Inborn errors of metabolism: Consistent with abnormal metabolic markers (carnitine, enzyme levels), developmental abnormalities, and potential for early childhood death.

+3. Congenital malformations: Consistent with abnormality of prenatal development or birth, and potential for obesity and early childhood death.

+4. Genetic syndromes: Consistent with developmental abnormalities, obesity, and increased risk of early childhood death.

+5. Perinatal complications: Consistent with abnormality of prenatal development or birth, and potential for neonatal/infant/childhood death.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Leukodystrophy: Consistent with intellectual disability, seizures, motor delay, abnormal cerebral white matter morphology, and potential early death. May not explain hypertyrosinemia or hyperphenylalaninemia.

+2. Phenylketonuria (PKU): Consistent with intellectual disability, seizures, and hyperphenylalaninemia. Does not typically involve white matter abnormalities, dyskinesia, or early death.

+3. Tyrosinemia type I: Consistent with intellectual disability, seizures, hypertyrosinemia, and potential early death. Does not typically involve white matter abnormalities or dyskinesia.

+4. Leigh syndrome: Consistent with intellectual disability, seizures, motor delay, abnormal cerebral white matter morphology, and potential early death. Does not typically involve metabolic abnormalities.

+5. Mitochondrial disorder: Consistent with intellectual disability, seizures, motor delay, abnormal cerebral white matter morphology, and potential early death. Does not typically involve metabolic abnormalities.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Consistent with decreased ceruloplasmin, increased urinary copper, copper accumulation in liver, and potential liver enzyme elevation. Key symptoms not reported: neurological or psychiatric manifestations.

+2. Hereditary fructose intolerance: Consistent with hypotonia, hepatomegaly, and amino acid imbalances. Key symptoms not reported: fructose intolerance, hypoglycemia, and failure to thrive.

+3. Glycogen storage disease: Consistent with hypotonia, hepatomegaly, and amino acid imbalances. Key symptoms not reported: muscle weakness, growth retardation, and specific enzyme deficiencies.

+4. Niemann-Pick disease: Consistent with hepatosplenomegaly and hypotonia. Key symptoms not reported: neurological manifestations, cherry-red spot in the eye, and specific enzyme deficiencies.

+5. Copper metabolism disorder (unspecified): Consistent with decreased ceruloplasmin, increased urinary copper, copper accumulation in liver, and potential liver enzyme elevation. Additional testing would be needed to determine the specific type.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Ataxia-telangiectasia (A-T): Consistent with ataxia, cerebellar atrophy, intellectual disability, and abnormal facial shape. Key symptom not reported: telangiectasias.

+2. Joubert syndrome: Consistent with cerebellar agenesis, ataxia, hypotonia, and abnormal facial shape. Intellectual disability may or may not be present.

+3. Trisomy 18 (Edwards syndrome): Consistent with intellectual disability, hypotonia, and abnormal facial shape. Does not typically involve cerebellar atrophy or ataxia.

+4. Leukodystrophy: Consistent with ataxia, intellectual disability, and potential brain imaging abnormalities. Specific symptoms do not clearly point to a specific leukodystrophy.

+5. Congenital muscular dystrophy: Consistent with hypotonia and potential intellectual disability. However, ataxia, cerebellar atrophy, and abnormal facial shape are not typical features.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential for severe developmental issues if untreated. Key symptom not reported: intellectual disability, seizures.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential for liver disease, neurological problems, and early mortality. Key symptoms not reported: liver dysfunction, kidney problems, rickets.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development and potential for multi-organ involvement leading to early mortality. Key symptoms not reported: specific physical abnormalities or organ system involvement.

+4. Severe congenital heart defect: Consistent with potential for abnormal prenatal development and early mortality. Key symptoms not reported: specific cardiac abnormalities or associated symptoms (e.g., cyanosis, heart failure).

+5. Chromosomal abnormality: Consistent with potential for abnormal prenatal development and multi-system involvement leading to early mortality. Key symptoms not reported: specific physical features or developmental delays associated with the chromosomal disorder.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with macrocephaly, hypotonia, abnormal cerebral morphology, increased lactate, and glutaric aciduria. May not explain hypercalcemia or abnormal lysine/carnitine levels.

+2. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with macrocephaly, hypotonia, abnormal cerebral morphology, and death in infancy. May not explain metabolic abnormalities.

+3. Mitochondrial disorder: Consistent with hypotonia, increased lactate, and potential neurological symptoms. May not fully explain macrocephaly, hypercalcemia, or specific metabolic abnormalities.

+4. Congenital disorder of glycosylation (CDG): Consistent with hypotonia, developmental delays, and potential metabolic abnormalities. Specific symptoms can vary widely among different CDG types.

+5. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with metabolic abnormalities, hypotonia, and potential neurological symptoms. May not fully explain macrocephaly or hypercalcemia.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential for developmental abnormalities, intellectual disability, and early death if untreated.

+2. Tyrosinemia: Consistent with hypertyrosinemia and potential for liver disease, neurological problems, and early death if untreated.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development and potential for multi-organ involvement leading to early mortality. Common symptoms not reported, such as dysmorphic features or specific organ abnormalities.

+4. Severe perinatal asphyxia: Consistent with potential for neonatal death or developmental abnormalities due to lack of oxygen during birth. Specific symptoms related to organ damage or neurological impairment not reported.

+5. Prematurity complications: Consistent with potential for neonatal death or developmental abnormalities due to premature birth. Specific symptoms related to respiratory distress, feeding difficulties, or other complications not reported.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Consistent with hypertyrosinemia, hyperphenylalaninemia, growth delays, and potential organ involvement. Key symptoms like developmental delays or neurological issues may not be reported.

+2. Congenital malformation syndrome: Matches microcephaly, prenatal abnormalities, severe short stature, and potential organ involvement. Specific dysmorphic features or other congenital anomalies may not be reported.

+3. Lysosomal storage disorder: Consistent with growth delays, organ involvement (effusions), and potential neurological manifestations. Specific symptoms like coarse facial features or skeletal abnormalities may not be reported.

+4. Chromosomal disorder: Could explain microcephaly, prenatal abnormalities, growth restriction, and potential organ involvement. Specific dysmorphic features or intellectual disability may not be reported.

+5. Congenital infection or teratogen exposure: Potentially accounts for microcephaly, prenatal abnormalities, and growth restriction. Metabolic abnormalities and organ involvement make this less likely, but specific exposure history is not provided.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorders (UCDs): Consistent with hyperammonemia, hyperglutaminemia, oroticaciduria, and potential death in childhood.

+2. Ornithine transcarbamylase deficiency (OTC deficiency): A specific type of UCD, consistent with the reported symptoms and potential early childhood death.

+3. Citrullinemia: Another type of UCD, consistent with hyperammonemia, hyperglutaminemia, oroticaciduria, and potential early childhood death.

+4. Organic acidemias: Consistent with hyperammonemia and vomiting, but may not fully explain the other reported symptoms.

+5. Liver disease: Consistent with hyperammonemia, but the presence of hyperglutaminemia and oroticaciduria suggests a more specific metabolic disorder.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, abnormal tyrosine levels, elevated urinary carboxylic acids, and potential developmental abnormalities. Key symptom not reported: intellectual disability.

+2. Maple Syrup Urine Disease (MSUD): Consistent with elevated urinary carboxylic acids and potential developmental abnormalities. Key symptoms not reported: maple syrup odor, lethargy.

+3. Congenital Hypothyroidism: Consistent with developmental abnormalities and obesity. Key symptoms not reported: specific thyroid function abnormalities.

+4. Organic Acidemia: Consistent with elevated urinary carboxylic acids, developmental abnormalities, and potential early death. Key symptoms not reported: specific metabolic crisis presentations.

+5. Chromosomal Abnormality: Consistent with developmental abnormalities, obesity, and potential early death. Key symptoms not reported: specific physical features or intellectual disability.",Hereditary metabolic disorders
['Pearson syndrome'],"+1. Mitochondrial disorder: Consistent with metabolic acidosis, neurological symptoms, multi-organ dysfunction, and potential mitochondrial dysfunction markers. Key symptoms not reported: muscle weakness, exercise intolerance, seizures.

+2. Inborn error of metabolism: Consistent with metabolic abnormalities, multi-organ involvement, and potential for early mortality. Key symptoms not reported: specific metabolic markers or patterns depending on the disorder.

+3. Congenital syndrome or chromosomal abnormality: Consistent with the wide range of symptoms affecting multiple systems. Key symptoms not reported: specific dysmorphic features or patterns associated with particular syndromes.

+4. Immunodeficiency disorder: Consistent with recurrent viral infections and hematological abnormalities. Key symptoms not reported: specific patterns of infections, lymphoid organ involvement, or autoimmune manifestations.

+5. Renal disorder: Consistent with significant renal dysfunction, including enlarged kidney, acute and chronic kidney disease, and renal Fanconi syndrome. Key symptoms not reported: specific patterns of proteinuria, hematuria, or electrolyte imbalances.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with broad/long/deep philtrum, anteverted nares, syndactyly, generalized hypotonia, hypocholesterolemia, elevated 8-dehydrocholesterol, elevated circulating 7-dehydrocholesterol concentration, feeding difficulties, and potentially neonatal death/death in infancy.

+2. Trisomy 18 (Edwards syndrome): Consistent with broad/long/deep philtrum, anteverted nares, syndactyly, generalized hypotonia, feeding difficulties, and potentially neonatal death/death in infancy. Does not typically involve cholesterol abnormalities.

+3. Prader-Willi syndrome: Consistent with generalized hypotonia and feeding difficulties. Does not typically involve the physical features or cholesterol abnormalities reported.

+4. Congenital disorders of glycosylation (CDG): Consistent with generalized hypotonia and feeding difficulties. Does not typically involve the physical features or cholesterol abnormalities reported.

+5. Other genetic or metabolic syndrome: The combination of physical features, metabolic abnormalities, and severity of symptoms may suggest a rare genetic or metabolic syndrome not listed above.",Hereditary metabolic disorders
['Acute intermittent porphyria'],"+1. Cystic fibrosis: Consistent with vomiting, abdominal pain, recurrent viral infections, and potential early mortality. Key symptoms like chronic lung disease and pancreatic insufficiency may not be reported.

+2. Severe combined immunodeficiency (SCID): Matches recurrent viral infections and potential early mortality. Gastrointestinal symptoms like vomiting and abdominal pain are less common.

+3. Chronic granulomatous disease (CGD): Aligns with recurrent viral infections and potential early mortality. Gastrointestinal symptoms are not typical.

+4. Organic acidemia or urea cycle disorder: Could explain vomiting, abdominal pain, recurrent infections (due to immune dysfunction), and potential early mortality. Specific metabolic abnormalities may not be reported.

+5. Inflammatory bowel disease (IBD): Consistent with vomiting and abdominal pain. However, recurrent viral infections and early mortality are less common features.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Argininemia: Consistent with hyperammonemia, argininuria, and abnormal circulating arginine concentration. May not present with hyperglycinuria or hyperglutaminemia.

+2. Citrullinemia: Consistent with hyperammonemia and elevated plasma citrulline. May not present with argininuria or abnormal circulating arginine concentration.

+3. Ornithine transcarbamylase deficiency: Consistent with hyperammonemia, metabolic acidosis, and neonatal death. May not present with specific amino acid abnormalities.

+4. Carbamoyl phosphate synthetase I deficiency: Consistent with hyperammonemia, metabolic acidosis, and neonatal death. May not present with specific amino acid abnormalities.

+5. Glycine encephalopathy (non-ketotic hyperglycinemia): Consistent with hyperglycinuria. Does not typically present with hyperammonemia or other amino acid abnormalities.",Hereditary metabolic disorders
[],"+1. Methylmalonic acidemia: Consistent with methylmalonic acidemia, methylmalonic aciduria, lethargy, hypotonia, developmental delay, and dehydration.
+2. Propionic acidemia: Consistent with lethargy, hypotonia, developmental delay, and metabolic acidosis (indicated by dehydration).
+3. Homocystinuria: Consistent with hyperhomocystinemia, developmental delay, and hypotonia.
+4. Urea cycle disorder: Consistent with hyperammonemia, lethargy, and dehydration.
+5. Fatty acid oxidation disorder: Consistent with lethargy, hypotonia, and metabolic decompensation (indicated by dehydration).",Hereditary metabolic disorders
['Very long chain acyl-CoA dehydrogenase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, abnormal amino acid levels, and potential for neonatal/infant death. Key symptom not reported: episodic vomiting, lethargy.

+2. Fatty acid oxidation disorder: Consistent with hypotonia, decreased free carnitine, abnormal amino acid levels. Key symptom not reported: hypoglycemia, hepatomegaly.

+3. Mitochondrial disorder: Consistent with hypotonia, hyperammonemia, abnormal amino acid levels. Key symptom not reported: lactic acidosis, seizures.

+4. Organic acidemia: Consistent with hyperammonemia, hypotonia, abnormal amino acid levels. Key symptom not reported: metabolic acidosis, ketosis.

+5. Carnitine deficiency: Consistent with decreased plasma free carnitine, hypotonia, hyperammonemia. Key symptom not reported: cardiomyopathy, muscle weakness.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Inborn error of metabolism: Hypertyrosinemia, hyperphenylalaninemia, potential developmental abnormalities, and neonatal death are consistent with this diagnosis. Key symptoms not reported: specific metabolic abnormalities or organ involvement.

+2. Congenital airway anomaly: Upper airway obstruction and potential neonatal death are consistent with this diagnosis. Key symptoms not reported: specific anatomical defects or associated anomalies.

+3. Chromosomal abnormality or genetic syndrome: Abnormality of prenatal development or birth, potential developmental abnormalities, and multi-system involvement are consistent with this diagnosis. Key symptoms not reported: specific chromosomal or genetic defect.

+4. Severe respiratory disorder: Chronic pulmonary obstruction, upper airway obstruction, and potential neonatal death are consistent with this diagnosis. Key symptoms not reported: specific respiratory pathology or underlying cause.

+5. Congenital heart defect: Abnormality of prenatal development or birth and potential neonatal death are consistent with this diagnosis. Key symptoms not reported: specific cardiac anomaly or associated findings.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Inborn error of metabolism (e.g., fatty acid oxidation disorder, organic acidemia): Consistent with decreased plasma free carnitine, decreased 3-hydroxyacyl-CoA dehydrogenase level, abnormal vitamin B12 concentration, hypoxemia, and early mortality. May not fully explain spasticity or gastrointestinal symptoms.

+2. Congenital malformation/chromosomal abnormality: Consistent with premature birth, early mortality, and multi-system involvement (neurological, gastrointestinal, metabolic). Specific malformation or syndrome would need to be identified based on additional testing.

+3. Severe perinatal complication (e.g., hypoxic-ischemic encephalopathy, sepsis): Consistent with premature birth, hypoxemia, and early mortality. May not fully explain metabolic abnormalities or gastrointestinal symptoms.

+4. Neuromuscular disorder (e.g., spinal muscular atrophy, muscular dystrophy): Consistent with spasticity and early mortality. May not fully explain metabolic abnormalities or gastrointestinal symptoms.

+5. Mitochondrial disorder: Consistent with multi-system involvement (neurological, gastrointestinal, metabolic), hypoxemia, and early mortality. Specific mitochondrial disorder would need to be identified based on additional testing.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Consistent with hypertyrosinemia and potential for early death. May not explain hyperphenylalaninemia or recurrent viral infections.

+2. Leukodystrophy: Consistent with potential for early death and some metabolic abnormalities. May not explain hypertyrosinemia, hyperphenylalaninemia, or recurrent viral infections.

+3. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Does not typically present with hypertyrosinemia or recurrent viral infections.

+4. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections and potential for early death. Does not typically present with metabolic abnormalities.

+5. Inherited metabolic disorder (unspecified): Consistent with metabolic abnormalities and potential for early death. Additional testing would be needed to identify the specific disorder.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Glycine encephalopathy (non-ketotic hyperglycinemia): Consistent with aminoaciduria, abnormal circulating glycine concentration, and elevated urinary carboxylic acid. Key symptom not reported: Severe neurological symptoms like seizures, lethargy, and developmental delays.

+2. Methylmalonic acidemia: Consistent with aminoaciduria and elevated urinary carboxylic acid. Key symptoms not reported: Vomiting, lethargy, and failure to thrive.

+3. Propionic acidemia: Consistent with aminoaciduria and elevated urinary carboxylic acid. Key symptoms not reported: Vomiting, lethargy, and metabolic acidosis.

+4. Isovaleric acidemia: Consistent with aminoaciduria and elevated urinary carboxylic acid. Key symptom not reported: Distinctive sweaty feet odor.

+5. Glutaric acidemia type I: Consistent with aminoaciduria and elevated urinary carboxylic acid. Key symptoms not reported: Macrocephaly (enlarged head size) and neurological symptoms like seizures and developmental delays.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Leukodystrophy: Delayed speech/language development, seizures, ataxia, motor delay, generalized hypotonia, and elevated urinary carboxylic acid are consistent with this group of metabolic disorders affecting the white matter of the brain.

+2. Mitochondrial disorder: Seizures, ataxia, motor delay, generalized hypotonia, and elevated urinary carboxylic acid (in some cases) could indicate a mitochondrial disease affecting energy production in cells.

+3. Rett syndrome: Delayed speech/language development, hyperactivity, seizures, ataxia, and motor delay are characteristic of this genetic disorder, primarily affecting girls. However, elevated carboxylic acid and early death are not typical.

+4. Autism spectrum disorder (ASD): Delayed speech/language development, hyperactivity, and motor delay are common in ASD, but seizures, ataxia, and elevated carboxylic acid are not typical features.

+5. Severe epileptic encephalopathy: The presence of seizures, developmental delays, and potential early death could suggest a severe form of epilepsy with associated brain dysfunction, but the other symptoms may not fit as well.",Hereditary metabolic disorders
['Argininosuccinic aciduria'],"+1. Organic acidemia: Consistent with metabolic acidosis, vomiting, and potentially hepatomegaly. Key symptom not reported: specific neurological manifestations.

+2. Fatty acid oxidation disorder: Consistent with metabolic acidosis, vomiting, hepatomegaly, and potentially tachycardia. Key symptom not reported: hypoglycemia.

+3. Congenital heart defect: Consistent with tachycardia and potentially metabolic acidosis, hepatomegaly (if causing heart failure). Key symptom not reported: specific cardiac murmur or cyanosis.

+4. Biliary atresia: Consistent with hepatomegaly, vomiting, and potentially metabolic acidosis. Key symptom not reported: jaundice or pale stools.

+5. Severe bronchopulmonary dysplasia: Consistent with tachypnea and potentially metabolic acidosis (if causing respiratory failure). Key symptom not reported: specific respiratory distress or oxygen requirement.",Hereditary metabolic disorders
['Gyrate atrophy of choroid and retina'],"+1. Methylmalonic acidemia: Consistent with anemia, hyperammonemia, malabsorption, and metabolic abnormalities. May not fully explain blindness, severe short stature, or specific amino acid abnormalities.

+2. Propionic acidemia: Consistent with anemia, hyperammonemia, malabsorption, and metabolic abnormalities. May not fully explain blindness, severe short stature, or specific amino acid abnormalities.

+3. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with hyperammonemia, hyperornithinemia, and hypoargininemia. Does not typically cause blindness or severe short stature.

+4. Maple syrup urine disease (MSUD): Consistent with hyperammonemia, hyperglycinemia, and abnormal amino acid levels. Blindness and severe short stature are not typical features.

+5. 3-phosphoglycerate dehydrogenase deficiency: Consistent with abnormal circulating serine concentration and some metabolic abnormalities. May not fully explain the entire symptom picture.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. May also present with developmental delays, seizures, and other neurological symptoms not reported.

+2. Tyrosinemia: Consistent with hypertyrosinemia. Can lead to liver disease, neurological problems, and early death if untreated.

+3. Congenital malformation syndrome: Consistent with abnormality of prenatal development. May involve multiple organ systems and cause early mortality.

+4. Severe perinatal asphyxia: Consistent with neonatal death. Can result in organ damage and developmental abnormalities.

+5. Chromosomal abnormality: Consistent with abnormal prenatal development and early mortality. May present with dysmorphic features or other congenital anomalies not reported.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, cerebral edema, neonatal death/death in infancy. May not exhibit generalized hypotonia or feeding difficulties in all cases.

+2. Organic acidemia: Consistent with hyperammonemia, cerebral edema, neonatal death/death in infancy. May not exhibit generalized hypotonia or feeding difficulties in all cases.

+3. Mitochondrial disorder: Consistent with generalized hypotonia, feeding difficulties, and potential for progressive neurological deterioration. Hyperammonemia and cerebral edema are less typical.

+4. Leigh syndrome: Consistent with generalized hypotonia, feeding difficulties, and potential for progressive neurological deterioration. Hyperammonemia and cerebral edema are less typical.

+5. Lysosomal storage disorder: Consistent with generalized hypotonia and feeding difficulties. Hyperammonemia, cerebral edema, and neonatal death/death in infancy are less typical.",Hereditary metabolic disorders
['Canavan disease'],"+1. Leukodystrophy: Consistent with abnormal myelination, seizures, motor delay, hypotonia, blindness, and hearing impairment. May not explain abnormal amino acid levels.

+2. Peroxisomal disorder: Consistent with neurological symptoms, vision and hearing loss, and abnormal amino acid levels. Severity and early onset may vary.

+3. Mitochondrial disorder: Consistent with neurological symptoms, seizures, and abnormal amino acid levels. May not fully explain the extent of sensory impairment.

+4. Lysosomal storage disorder: Consistent with progressive neurological deterioration, seizures, vision and hearing loss. Severity and specific symptoms may vary.

+5. Inherited metabolic disorder: Consistent with abnormal amino acid levels and neurological symptoms. Specific diagnosis would depend on the metabolic pathway affected.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Congenital brain malformation or genetic disorder: Hydrocephalus, microcephaly, intellectual disability, strabismus, nystagmus, death in infancy/childhood. May not exhibit metabolic abnormalities.

+2. Methylmalonic acidemia: Hyperhomocystinemia, methylmalonic aciduria, intellectual disability, hydrocephalus, microcephaly, respiratory insufficiency. May not have severe vision problems or dyskinesia.

+3. Homocystinuria: Hyperhomocystinemia, intellectual disability, hydrocephalus, microcephaly, strabismus, nystagmus, dyskinesia. May not have respiratory issues or early death.

+4. Neurodegenerative disorder: Intellectual disability, strabismus, nystagmus, dyskinesia, death in childhood. May not have metabolic abnormalities or hydrocephalus/microcephaly.

+5. Complications of prematurity: Premature birth, respiratory insufficiency, hydrocephalus, intellectual disability, neonatal death. May not have metabolic abnormalities or severe vision/movement disorders.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Consistent with vomiting, gastrointestinal inflammation, abnormal carnitine levels, and decreased 3-hydroxyacyl-CoA dehydrogenase. May present with prenatal abnormalities and neonatal death.

+2. Organic acidemia: Consistent with vomiting, gastrointestinal inflammation, and metabolic abnormalities. May present with prenatal abnormalities and neonatal death. Key symptoms like metabolic acidosis, hyperammonemia, or specific metabolite elevations were not reported.

+3. Mitochondrial disorder: Consistent with multisystem involvement, including gastrointestinal symptoms, metabolic abnormalities, and potential prenatal/neonatal complications. Specific symptoms like neurological manifestations, lactic acidosis, or muscle weakness were not reported.

+4. Congenital disorder of glycosylation: Consistent with multisystem involvement, including gastrointestinal symptoms and potential prenatal/neonatal complications. Specific symptoms like developmental delay, neurological manifestations, or coagulopathy were not reported.

+5. Severe combined immunodeficiency: Consistent with potential gastrointestinal inflammation and neonatal complications. However, specific symptoms like recurrent infections or failure to thrive were not reported.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Inborn error of metabolism: Consistent with hypotonia, metabolic acidosis, hyperammonemia. May not explain leukopenia or neonatal death.

+2. Mitochondrial disorder: Consistent with hypotonia, metabolic acidosis, multi-organ involvement. Hyperammonemia is not a typical feature.

+3. Congenital myopathy: Consistent with generalized hypotonia. Other reported symptoms are not commonly associated.

+4. Congenital infection: Hypotonia and multi-organ involvement could be explained, but reported symptoms do not strongly suggest an infectious etiology.

+5. Genetic syndrome: Hypotonia, metabolic acidosis, and neurological symptoms could fit certain syndromes, but the specific symptoms reported do not clearly point to a specific diagnosis.",Hereditary metabolic disorders
['Tyrosinemia type 2'],"+1. Richner-Hanhart syndrome: Consistent with keratitis, conjunctivitis, photophobia, hyperkeratosis, intellectual disability, seizures, and death in childhood. Key symptom not reported: palmoplantar keratoderma (thickening of skin on palms and soles).

+2. Tyrosinemia type II: Consistent with keratitis, conjunctivitis, photophobia, hyperkeratosis, intellectual disability, seizures, hypertyrosinemia, and death in childhood. Key symptom not reported: painful palmoplantar keratosis.

+3. Vernal keratoconjunctivitis: Consistent with keratitis, conjunctivitis, photophobia, and epiphora. Key symptoms not reported: itching, eye discharge, and seasonal exacerbation.

+4. Herpes simplex keratitis: Consistent with keratitis, conjunctivitis, photophobia, and epiphora. Key symptoms not reported: eye pain, blurred vision, and history of herpes simplex virus infection.

+5. Stevens-Johnson syndrome: Consistent with keratitis, conjunctivitis, photophobia, and hyperkeratosis. Key symptoms not reported: widespread skin rash, mucosal involvement, and fever.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, abnormal tyrosine levels, potential prenatal development abnormalities, and complications leading to death in infancy or early adulthood if untreated. Key symptom not reported: intellectual disability or developmental delays.

+2. Maple syrup urine disease (MSUD): Consistent with abnormal tyrosine levels, potential prenatal development abnormalities, and complications leading to death in infancy or early childhood if untreated. Key symptoms not reported: maple syrup odor in urine, lethargy, and poor feeding.

+3. Tyrosinemia: Consistent with abnormal tyrosine levels and potential complications leading to early death if untreated. Key symptoms not reported: liver dysfunction, kidney dysfunction, and neurological symptoms.

+4. Congenital malformations or genetic syndromes: Consistent with abnormality of prenatal development or birth, and potentially other reported symptoms depending on the specific condition. Additional information on the nature of the malformation or syndrome would be needed for a more specific diagnosis.

+5. Inborn errors of metabolism: The reported symptoms could potentially be caused by various inborn errors of metabolism affecting amino acid metabolism or other metabolic pathways. Additional testing would be required to identify the specific disorder.",Hereditary metabolic disorders
[],"+1. Urea cycle disorder: Consistent with hyperammonemia, cyanosis, seizures, and potential for neonatal death. Key symptoms include vomiting, lethargy, and respiratory distress, which are not mentioned.

+2. Organic acidemia: Matches the presence of 3-hydroxydicarboxylic aciduria, hyperammonemia, and potential for early death. Common symptoms like vomiting, lethargy, and failure to thrive are not reported.

+3. Mitochondrial disorder: Could explain the combination of cyanosis, seizures, and potential for early death due to impaired energy production. Additional symptoms like muscle weakness, developmental delays, and vision/hearing problems are not mentioned.

+4. Fatty acid oxidation disorder: Consistent with cyanosis, seizures, and potential for early death due to impaired energy production during periods of fasting or illness. Symptoms like hypoglycemia, vomiting, and lethargy are not reported.

+5. Glycogen storage disease: Could potentially explain the presence of seizures and early death, but the other reported symptoms are not typical of this group of disorders.",Hereditary metabolic disorders
['Alkaptonuria'],"+1. Metabolic disorder: Consistent with vomiting, dark urine, and potential death in infancy. Key symptoms like lethargy, poor feeding, or developmental delays may also be present.

+2. Biliary atresia: Consistent with dark urine, vomiting, and potential death in infancy if left untreated. Jaundice and pale stools are common symptoms not reported.

+3. Congenital infection: Consistent with vomiting, potential death in infancy. Additional symptoms like rash, hearing loss, or neurological abnormalities may be present but not reported.

+4. Pyloric stenosis: Consistent with persistent vomiting, which can lead to dehydration and dark urine. However, death in infancy is less common with this condition if treated promptly.

+5. Congenital brain or spinal cord abnormality: Consistent with potential death in infancy and vomiting, but dark urine may not be directly related. Additional neurological symptoms like seizures or developmental delays may be present but not reported.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, elevated urinary carboxylic acid, seizures, lethargy, growth delay, metabolic acidosis, and feeding difficulties. Key symptom not reported: maple syrup odor in urine and body fluids.

+2. Organic acidemia: Consistent with metabolic acidosis, lethargy, seizures, growth delay, and elevated urinary carboxylic acid. Specific organic acidemia would need to be determined based on further testing.

+3. Urea cycle disorder: Consistent with hyperammonemia, lethargy, seizures, and metabolic acidosis. Specific disorder would need to be identified based on further testing.

+4. Mitochondrial disorder: Consistent with metabolic acidosis, lethargy, seizures, growth delay, and feeding difficulties. Specific disorder would need to be identified based on further testing.

+5. Leukodystrophy: Consistent with neurological symptoms (seizures, lethargy, drowsiness, sleep abnormalities), developmental delays, and severe hearing impairment. Specific type would need to be determined based on further testing.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, abnormal amino acid levels, neurological symptoms, and potential liver dysfunction. Key symptom not reported: elevated blood urea nitrogen.

+2. Mitochondrial disorder: Consistent with multi-system involvement, metabolic abnormalities, neurological symptoms, and potential organ dysfunction. Key symptom not reported: lactic acidosis.

+3. Severe combined immunodeficiency: Consistent with recurrent viral infections and potential organ involvement. Key symptom not reported: lymphopenia or abnormal lymphocyte subsets.

+4. Leukodystrophy or nucleotide metabolism disorder: Consistent with oroticaciduria, uraciluria, neurological symptoms, and potential metabolic abnormalities. Key symptom not reported: specific white matter changes on neuroimaging.

+5. Severe epileptic encephalopathy or neurodegenerative disorder: Consistent with neurological symptoms, metabolic abnormalities, and potential organ dysfunction. Key symptom not reported: specific seizure types or patterns.",Hereditary metabolic disorders
